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1.	  INTRODUCTION	  
1.1. Epidemiology	  Breast	  Cancer	  	  Worldwide,	  breast	  cancer	   is	  still	   the	  most	  common	  malignant	  tumour	  diagnosed	  in	  women	   with	   an	   calculated	   1.7	   million	   new	   breast	   cancer	   cases	   and	   522,000	   breast	  cancer	  associated	  deaths	  in	  2012	  (1).	  To	  continue,	  invasive	  breast	  cancer	  remains	  to	  be	  considered	  one	  of	   the	  utmost	   challenges	   for	   specialists	   to	   regulate	  and	  additionally	   to	  improve	  the	  survival	  of	  patients	  (2).	  Nevertheless,	  the	  survival	  of	  breast	  cancer	  patients	  is	   strongly	   related	   to	   prognostic	   factors	   including	   tumour	   size,	   hormone-­‐receptor-­‐profile	  and	  manifestation	  of	  metastases	  (3).	  Even	  though	  the	  treatment	  options	  of	  breast	  cancer	   counting	   surgery,	   chemotherapy,	   aromatase	   inhibitors	   and	   hormone	   receptor	  modulators	   (4-­‐6)	   have	   tremendously	   advanced	   over	   the	   former	   centuries,	   yet	   the	  constantly	   high	   mortality	   numbers	   especially	   due	   to	   tumour	   metastasis	   to	   the	   vital	  organs	   and	   lymph	   node	   remain	   (7).	   Mortality	   is	   predominantly	   correlated	   to	   distant	  metastatic	  growth	  (7,	  8).	  	  	  
1.2. Circulating	  tumour	  cells	  and	  the	  SUCCESS	  Study	  Group	  Previous	   studies	   have	   established	   an	   association	   between	   poor	   prognosis	   and	   the	  detection	  of	  circulating	  tumour	  cells	  (CTCs)	  before	  the	  start	  of	  systemic	  treatment	  (9).	  Also	  referred	  to	  as	   'liquid	  biopsy',	   this	  method	  of	  detection	  has	  established	  itself	  as	  an	  important	   device	   for	   assessing	   and	   observing	   the	   efficiency	   of	   treatments	   in	   patients	  with	   breast	   cancer.	   The	   technique	   can	   refer	   to	   molecular	   analysis	   of	   the	   tumour’s	  genetic	   structures	   grounded	   on	   circulating	   genetic	   material	   in	   the	   peripheral	   blood	  originated	   from	  CTCs	   	   (10,	   11).	   Furthermore,	   CTCs	   in	   the	  peripheral	   blood	  have	  been	  found	   to	   be	   a	   prognostic	  marker	   for	   reduced	  disease	   free	   survival	   (DFS),	   distant	  DFS,	  breast	   cancer–specific	   DFS	   and	   overall	   survival	   (OS)	   before	   the	   start	   of	   systemic	  treatment	  (9,	  12-­‐15).	  The	  technology	  for	  identifying	  CTCs	  has	  evolved	  from	  simple	  cell	  counting	  into	  innovative	  molecular	  subtyping	  (16)	  over	  the	  past	  years.	  This	  process	  has	  established	  a	  minimally	  invasive	  method	  in	  early	  carcinoma	  detection	  and	  furthermore	  in	  disease	  monitoring.	  CTCs	  are	  thought	  to	  originate	  from	  the	  primary	  tumour	  and	  even	  considered	  to	  obtain	  genetic	  heterogeneity	  during	  evolution,	  as	  a	  conclusion	  CTC	  values	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shortly	   after	   commence	   of	   treatment	   deliver	   complementary	   information	   regarding	  therapy	  response	  (15).	  	  The	   SUCCESS	   study	  was	   one	   of	   the	   first	   trials	   to	   determine	   the	   role	   of	   CTCs	   in	  patients	  with	   breast	   cancer.	   The	   study	   specified	   the	   strong	   prognostic	   significance	   of	  CTCs	   being	   associated	  with	   a	   less	   favourable	   outcome,	  when	   detected	   in	   early	   breast	  cancer	   before	   the	   start	   of	   systemic	   adjuvant	   treatment	   and	   after	   adjuvant	  chemotherapy,	  in	  a	  large	  patient	  cohort	  (17).	  	  
	  
1.3. Immune	  response	  of	  T-­‐lymphocytes	  &	  Angiogenic	  cytokines	  	  The	   overall	   aim	   and	   intention	   of	   this	   study	   concerning	   Paper	   1,2	   and	   3	   was	   the	  evaluation	  of	  cytokines	  and	  the	  lymphatic	  system	  as	  an	  indicator	  for	  CTC	  involvement	  in	  patients	  with	  breast	  cancer.	  Having	  explained	  the	  significant	  and	  crucial	  role	  of	  CTCs	  in	  breast	  cancer	  patients,	  the	  determination	  of	  CTCs	  is	  however	  still	  a	  time	  consuming	  and	  high-­‐priced	  method.	  Furthermore,	   it	  has	  become	  increasingly	  evident	  that	  not	  only	  the	  breast	   cancer	   cells	   itself,	   but	   also	   the	  microenvironment	   of	   the	   tumour	   including	   the	  immunological	   reaction	   plays	   a	   significant	   role	   in	   terms	   of	   tumour	   progression,	  metastasis	  formation	  and	  treatment	  response	  (18).	  In	  concern	  to	  the	  arising	  significance	  of	  the	  lymphatic	  system	  involvement	  and	  cytokine	  measurement	  in	  cancer	  therapy,	  the	  intention	   of	   this	   analysis	   was	   therefore	   the	   specific	   evaluation	   of	   cytokine	   profiles	  (Paper	   2	   &	   3)	   and	   tumour-­‐angiogenesis	   markers	   (Paper	   1)	   in	   association	   to	   CTC	  involvement	   in	   patients	   with	   the	   primary	   diagnosis	   of	   breast	   cancer	   (19).	   	   The	  involvement	   of	   T-­‐Lymphocytes	   and	   their	   cytokines	   similarly	   to	   vascular	   markers	   are	  proved	  to	  interact	  with	  tumour	  cells	  and	  show	  an	  impact	  on	  the	  patient’s	  prognosis	  (20).	  T-­‐lymphocytes	  and	  their	  distinct	  maturation	  to	  cytokines	  and	  chemokines	  are	  known	  to	  be	   a	   vital	   factor	   of	   the	   adaptive	   immune	   response	   (21).	   Through	   their	   tumour-­‐promoting	   or	   tumour-­‐suppressive	   properties	   on	   critical	   cell	   derivation,	   the	  arrangements	   of	   cytokines	   that	   stimulate	   helper	   T-­‐lymphocyte	   maturation	   can	  furthermore	   through	   different	   interaction	   lead	   to	   the	   expression	   of	   both	   pro-­‐inflammatory	   or	   anti-­‐inflammatory	   cytokines	   (22-­‐24).	   Through	   this	   specified	   function	  cytokines	   and	   chemokine’s	   are	   able	   to	   stimulate	   the	   cancers	   progress.	   Their	   role	   has	  been	   described	   to	   be	   an	   important	   prognostic	   factor	   in	   the	   presence	   of	   breast	   cancer	  tumours	  (21).	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Moreover,	   vascular	   tumour	   angiogenesis	   also	   acts	   as	   a	   vital	   component	   in	   the	  development	  and	  progression	  of	  breast	  cancer.	  Similar	   to	   the	  cytokine	  and	  chemokine	  pathway	  it	   is	  understood	  that	  angiogenesis	   in	  tumours	   is	  part	  of	  a	  multistep	  evolution	  involving	  the	  signalling	  between	  breast	  cancer	  cells	  and	  numerous	  cell	  varieties	  within	  the	  tumours	  microenvironment	  (3,	  25).	  The	  close	  relationship	  displays	  how	  a	  range	  of	  proangiogenic	   cytokines	   yielded	   by	   overexpression	   of	   factors	   by	   the	   tumour	   on	   the	  other	  hand	  promote	  angiogenesis	  (26).	  Neoangiogenesis	  is	  defined	  as	  a	  process	  of	  new	  blood	   capillary	   development	   from	   pre-­‐existing	   vessels,	   essentially	   in	   both	   embryonic	  and	   postnatal	   growth	   such	   as	   in	   the	   modification	   of	   numerous	   organ	   structures	   and	  specifically	   in	   tumour	   development	   and	   expansion	   (25).	   The	   progression	   of	   neo-­‐vascularisation	   is	   referred	   to	   as	   the	   “angiogenic	   switch”	   (3,	   27),	   where	   the	   balance	  amongst	  pro-­‐	  and	  antiangiogenic	   cytokines	  and	  chemokines	   slender	   for	  proangiogenic	  markers	  (26).	  This	  clearly	  illustrates	  the	  interactions	  of	  the	  Immune	  system,	  describing	  progression	  to	  a	  growing	  vascularized	  tumour	  and	   finally	   to	  malignant	  behaviour	  (26-­‐28).	  	  
	  
	  
	  	  	  	  Figure	  1	  (29)	  	  	  	  	  Overview	  of	  the	  TH1,	  TH2,	  TH9,	  TH17	  immune	  response	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The	  intention	  of	  this	  study	  concerning	  paper	  1,2	  and	  3	  was	  therefore	  to	  examine	  the	   distribution	   of	   T	   helper	   (TH)	   1,	   TH2,	   TH17,	   Regulatory	   T	   cells	   (Treg)	   and	   TH9	  cytokines	   of	   the	   T-­‐lymphocyte	   immune	   response	   including	   angiogenesis	  markers	   and	  reveal	  the	  differences	  of	  cytokine	  levels	  in	  breast	  cancer	  patients	  of	  the	  SUCCESS	  study	  group	  with	   respect	   to	  CTC	   involvement,	   histopathological	   grading,	   lymph	  node	   status,	  hormone	   receptor	   type,	   TNM	   classification	   and	   survived	   breast	   cancer	   patients	   vs.	  deceased	   tumour	   associated	  patients.	   The	   assessment	   of	   certain	   cytokine	   profiles	   and	  furthermore	  the	  evaluation	  of	  their	  functions	  could	  help	  for	  a	  revised	  understanding	  of	  the	  illness.	  It	  could	  offer	  new	  clinical	  perspectives	  by	  enhancing	  personalised	  treatment	  opportunities	   in	   regards	   to	   the	   tumour	   phenotype,	   furthermore	   allow	   a	   profounder	  understanding	   of	   how	   immunological-­‐related	   genes	   may	   influence	   breast	  carcinogenesis,	  evaluating	  the	  discrete	  risk	  of	  patients	  at	  the	  time	  of	  primary	  diagnosis	  and	  improve	  therapy	  observation.	  	  
	  
1.3.1. Angiogenic	  cytokines	  (Paper	  1)	  	  The	  cytokines	  belonging	  to	  the	  vascular	  endothelial	  growth	  factor	  (VEGF)	  family	  and	   their	   significant	   involvement	   in	   angiogenesis	   have	   been	   substance	   of	   major	  relevance.	  The	  VEGF	  family	  is	  so	  far	  known	  to	  include	  six	  related	  gene	  members	  being	  VEGF,	   VEGF-­‐B,	   VEGF-­‐C,	   VEGF-­‐D,	   VEGF-­‐F	   and	   placental	   growth	   factor	   (PIGF).	   They	   are	  described	  as	  regulators	  of	  angiogenesis	  or	   lymphangiogenesis	  or	  of	  both	  processes	   (3,	  26,	   30).	   	   Many	   studies	   have	   already	   focused	   on	   establishing	   a	   link	   of	   the	   precarious	  involvement	   of	   those	   markers	   with	   tumour	   evolution	   and	   have	   therefore	   become	   a	  promising	  focus	  in	  cancer	  therapy	  (3).	  It	  is	  understood	  that	  angiogenesis	  in	  carcinomas	  is	  part	  of	  a	  multistep	  evolution	  including	  the	  signalling	  between	  breast	  cancer	  cells	  and	  multiple	   other	   cell	   types	   within	   the	   tumours	   microenvironment	   (3,	   25).	   It	   has	   been	  implicated	   that	   the	  mentioned	  markers	   bind	  with	   various	   affinity	   to	   one	   of	   the	   three	  tyrosine	  kinase	  receptors	  also	  recognised	  as	  vascular	  endothelial	  growth	  factor	  receptor	  VEGFR-­‐1	   (sFlt1),	   VEGFR-­‐2	   and	   VEGFR-­‐3	   (31-­‐33),	   instructing	   a	   signalling	   cascade	  endorsing	   survival,	   progression	   and	   migration	   of	   carcinoma	   cells	   (3,	   34).	   Enhanced	  VEGF	  levels	  implement	  a	  well-­‐established	  indicator	  of	  unfortunate	  prognosis	  in	  tumour	  patients	   (35).	   On	   the	   other	   hand,	   PIGF	   and	   sFlt1	   levels	   have	   predominantly	   been	  associated	  to	  preeclampsia,	  in	  regards	  to	  breast	  cancer	  these	  markers	  have	  so	  far	  been	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associated	  with	  a	  lower	  risk	  of	  illness	  later	  in	  life	  (36,	  37).	  Paper	  1	  therefore	  focuses	  on	  analyzing	   the	   distribution	   of	   the	   angiogenic	   markers	   sFlt1,	   PlGF,	   VEGF,	   VEGF-­‐C	   and	  VEGF-­‐D	  and	  disclose	  the	  differences	  of	  their	  expression	  in	  breast	  cancer	  patients	  of	  the	  SUCCESS	   study	   group	   in	   terms	   of	   CTC	   involvement,	   histo-­‐pathological	   grading,	   lymph	  node	   metastasis,	   hormone	   receptor	   status,	   TNM	   classification	   and	   survived	   breast	  cancer	  patients	  vs.	  deceased	  tumour	  associated	  patients.	  	  
1.3.2. TH1	  cytokines	  immune	  response	  (Paper	  2)	  Cytokines	  belonging	  to	  the	  TH1	  immune	  response	  are	  implied	  to	  play	  a	  key	  part	  in	  phagocytic	  and	  intracellular	  defence	  (22)	  and	  have	  been	  subject	  of	  numerous	  studies.	  Analyses	  have	  suggested	  specific	  TH1	  expressions	  appear	   to	  correlate	  with	  TNM	  stage	  and	   lymph	   node	   involvement	   in	   breast	   cancer	   patients.	   Paper	   2	   focuses	   on	   the	  distribution	   for	   the	  TH1	   cytokines:	   Interferon	   gamma	   (IFN-­‐γ),	   Tumour	  necrosis	   factor	  alpha	   (TNF-­‐α),	   Interleukin	   (IL)-­‐12,	   IL-­‐1α,	   IL-­‐1β,	   IL-­‐2	   and	   IL-­‐18	   to	   evaluate	   profiles	   as	  marker	   for	   CTC	   involvement	   regarding	   specific	   breast	   cancer	   criteria	   as	   mentioned	  before,	   in	   hindsight	   to	   the	   implied	   cytokine	   manners	   stated	   above.	   For	   example,	  increased	  IFN-­‐γ	  values	  are	  associated	  with	  a	  positive	  outcome	  in	  breast	  cancer	  patients	  (38),	  while	  the	  existence	  of	  the	  IL-­‐1	  system	  was	  discovered	  to	  inversely	  correlate	  with	  local	  sex	  steroid	  receptor	  expression,	  stressing	  an	  enhanced	  malignant	  behaviour	  (39).	  IFN-­‐γ	  is	  even	  associated	  to	  a	  protective	  role	  against	  carcinomas	  by	  promoting	  apoptosis	  by	  enhancing	  cytotoxic	  T	  lymphocyte	  activity	  and	  expressing	  influence	  on	  p53	  (38,	  40).	  Presumed	  that	  IFN-­‐γ	  genetic	  polymorphisms	  might	  even	  be	  significantly	  related	  with	  a	  higher	  risk	  of	  breast	  cancer,	  its	  detection	  in	  correlation	  to	  CTCs	  is	  of	  major	  interest	  (41).	  IL1-­‐α	   is	  a	  TH1	  cytokine	  that	  on	  the	  other	  hand	  is	  hypothesized	  to	  derive	   from	  tumour	  cells	   itself	   (42).	   Implying	   that	   senescence	   increases	   in	   IL-­‐1α	   expression	   to	   generate	   a	  microenvironment	  that	  is	  beneficial	  to	  metastatic	  disease	  progression	  in	  cancer	  patients	  (42),	   suggesting	   an	   IL1-­‐α	   involvement	   in	   circulation	   specific	   metastasis	   opposed	   to	  metastasis	  via	  the	  lymphatic	  system.	  Furthermore,	   it	   is	  suggested	  that	  IL-­‐1α	  expressed	  on	   malignant	   cells	   stimulate	   an	   anti-­‐tumour	   immunity	   (43,	   44).	   In	   contrast,	   IL-­‐1β,	  originating	   from	   the	  microenvironment	   or	   the	  malignant	   breast	   carcinoma	   cells	   itself,	  triggers	   inflammation	   that	   endorses	   invasiveness	   and	   encourages	   tumour	   resolved	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suppression	  (39,	  43,	  44).	   IL-­‐12	  on	  the	  other	  hand	  is	  supposed	  to	  play	  the	  most	  critical	  part	  for	  the	  induction	  of	  TH1	  cytokines	  responses	  (22).	  	  Significantly	  enhanced	  IL-­‐12p40	  expression	  combined	  with	  significant	  increase	  in	  quantity	  of	  lymphocytes,	  CD4+,	  CD8+,	  Natural	   killer	   (NK)	   cells	   and	   C-­‐reactive	   protein	   (CRP)	   has	   been	   stated	   for	   a	   clinical	  benefit,	  as	  opposed	  to	  tumour	  growth,	  predominantly	  in	  hormone	  responsive	  metastatic	  breast	  cancer(45).	  Furthermore,	  IL-­‐12	  is	  emphasised	  to	  express	  an	  anti-­‐angionetic	  effect	  and	   is	   implied	   to	   induce	   a	   T-­‐cell	   based	   anti-­‐tumour	   immune	   response	   efficient	   of	  eradicating	   disseminated	   cancer	   cells	   (46-­‐48).	   	   IL-­‐12	   cytokines	   in	   intra-­‐tumour	  treatment	   in	   combination	   with	   other	   cytokines	   in	   breast	   cancer	   patients	   induce	  infiltration	  by	  polymorphonuclear	  cells,	  dendritic	  cell	  antigen	  presentation	  and	  CD8+	  T-­‐cells	  resulting	  in	  tumour	  regression	  (46,	  49).	  	  IL-­‐12	  local	  therapy	  has	  revealed	  in	  certain	  studies,	  stimulate	  specific	  antitumor	  T-­‐cells	   in	   lymph	  nodes	  thus	  ensuing	   in	  a	  memory	  immune	  response	  (46,	  48,	  49).	  	  	  
1.3.3. TH2	  cytokines	  immune	  response	  (Paper	  3)	  Certain	   cytokines	   belonging	   to	   the	   TH2	   immune	   response	   and	   found	   at	   increased	  levels	   in	   patients	   with	   carcinomas	   are	   correlated	   with	   inferior	   prognosis	   in	   terms	   of	  overall	  and	  DFS	  (50).	  Therefore,	  the	  investigation	  of	  a	  panel	  of	  TH2	  cytokines	  including	  IL-­‐4,	   IL-­‐5,	   IL-­‐6,	   IL-­‐8	   and	   IL-­‐13	   in	   a	   group	   of	   patients	   diagnosed	  with	   breast	   cancer	   in	  regards	  to	  the	  presence	  or	  absence	  of	  CTCs	  in	  hindsight	  to	  specific	  breast	  cancer	  criteria	  listed	  above	  is	  of	  major	  interest.	  To	  continue,	  literature	  has	  described	  the	  role	  of	  IL-­‐4	  to	  be	  part	  of	  the	  pathogenesis	  of	  cancer	  and	  expansion	  of	   local	  metastasis,	  particularly	   in	  colorectal	   cancer	   (51,	   52).	   Enhanced	   IL-­‐4	   levels	   are	   emphasized	   to	   be	   responsible	   for	  increasing	  tumour	  cell	  resistance	  to	  apoptosis	  (53).	  To	  continue,	  the	  increased	  presence	  of	  IL-­‐5	  in	  bladder	  cancer	  was	  described	  to	  enhance	  the	  migration	  and	  invasion	  of	  cancer	  cells	   via	   extracellular-­‐signal-­‐regulated	   kinases	   (ERK)	   1/2-­‐mediated	   Matrix	  metallopeptidase	  9	  (MMP-­‐9)/	  nuclear	  factor	  k-­‐light-­‐chain-­‐enhancer	  of	  activated	  B	  cells	  (NF-­‐B)/	  Activator	  protein	  1	   (AP-­‐1)	  pathway	   (54).	  The	  pro	   inflammatory	  cytokine	   IL-­‐6	  on	   the	   other	   hand	   is	   held	   responsible	   for	   tumour	   progress	   and	   differentiation	   in	  prostate	   cancer	   by	   promoting	   a	   proliferative	   and	   anti-­‐apoptotic	   effect	   (55).	   IL-­‐6	   level	  found	   in	   the	   sera	   of	   cancer	   patients	   is	   presumed	   to	   be	   a	   potential	   biomarker	   for	  predicting	  disease	  progression	  in	  colorectal	  cancer	  (56).	  Analyses	  furthermore	  suggest	  a	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correlation	   between	   IL-­‐8	   and	   neo-­‐vascularization	   (Paper	   1&3)	   thus	   encouraging	  metastatic	  spread	  (57,	  58).	  IL-­‐13	  on	  the	  other	  hand	  is	  described	  to	  negatively	  modulate	  the	  effective	  development	  of	  TH1	  immune	  response	  (Paper	  2&3)	  (59).	  IL-­‐13	  is	  implied	  to	   exert	   autocrine	   progress-­‐promoting	   effects	   and	   its	   expression	   correlates	   with	  evolution	  of	  lymph	  node	  metastases	  in	  human	  pancreatic	  cancer	  (60).	  Measurement	  and	  interpretation	   of	   TH2	   cytokines	   levels	   in	   breast	   cancer	   patients	   could	   thus	   assist	   to	  acquire	  new	  prognostic	  parameters	  and	  therapeutic	  strategies.	  	  
1.4. Study	  outline	  and	  Patients	  included	  	  As	   described	   before,	   SUCCESS	   was	   a	   prospective,	   randomized	   adjuvant	   study	  comparing	   three	   cycles	   of	   fluorouracil-­‐epirubicin-­‐cyclo-­‐phosphamide	   (FEC;	  500/100/500mg/m2)	  followed	  by	  3	  cycles	  of	  docetaxel	  (100mg/m2)	  every	  3	  weeks	  vs.	  three	  cycles	  of	  FEC	  followed	  by	  3	  cycles	  of	  gemcitabine	  (1000mg/m2	  d1,8)-­‐docetaxel	  (75	  mg/m2)	   each	   3	   weeks.	   After	   the	   completion	   of	   chemotherapy,	   the	   patients	   were	  randomized	   a	   second	   time	   for	   receiving	   either	   2	   or	   5	   years	   of	   zoledronate.	   Hormone	  receptor–positive	   women	   moreover	   received	   suitable	   endocrine	   treatment.	   Suitable	  patients	  were	  defined	  as	  women	  with	  breast	  cancer	  (Lymph	  node	  positive	  subgroup	  and	  Lymph	   node	   negative	   subgroup	   with	   high	   risk	   trades	   including	   grade	   3	   tumour,	  hormone	  receptor	  negative,	  age	  under	  35,	  ≥	  pT2)	  who	  willingly	  acknowledged	   to	   take	  part	   in	   the	   SUCCESS	   study	   (see	   homepage:	   http://www.success-­‐studie.de).	   The	   study	  was	  conducted	  as	  defined	  by	  the	  SUCCESS	  Study	  group	  (17).	  	  The	  patients	  included	  in	  this	  study	  concerning	  Paper	  1,2	  and	  3	  were	  200	  patients	  of	   the	   SUCCESS	   study	   and	   assigned	   into	   two	   groups:	   100	   Patients	   were	   CTC	   positive	  (group	  1)	  and	   the	  other	  100	  Patients	  were	  CTC	  negative	   (group	  2).	  These	   two	  groups	  were	   subsequently	   framed	   and	   investigated	   accordingly.	   Patients	   from	   respectively	  groups	  were	  matched	   into	  pairs	  of	   two	  according	   to	  histo-­‐pathological	  grading,	   lymph	  node	  involvement,	  hormone	  receptor	  type,	  TNM	  classification	  and	  survived	  patients	  vs.	  deceased	   patient’s	   tumour	   associated.	   Out	   of	   the	   200	   patient	   samples	   that	   were	  considered,	  a	  total	  of	  160	  patients	  were	  still	  alive	  at	  last	  observation	  after	  end	  of	  therapy	  and	  40	  patients	  had	  deceased	  during	  therapy	  tumour	  associated.	  	  The	  groups	  examined	  enclosed	  98	  patients	  graded	  G2	  and	  102	  patients	  graded	  G3.	  Matching	  criteria	  of	  the	  200	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patient	   collective	  did	  not	   include	  patients	  graded	  G1.	  Tumour	   stage	  of	   the	  anamnestic	  diagnosis	   was	   classified	   according	   to	   the	   TNM-­‐classification,	   which	   was	   conducted	  correspondingly	  to	  the	  WHO	  System	  (61).	  The	  matching	  of	  patients	  was	  accomplished	  in	  regards	  to	  the	  criteria	  at	   the	  time	  of	  primary	  diagnosis.	  The	  histo-­‐pathological	  grading	  was	  classified	  fitting	  to	  the	  Bloom	  and	  Richardson	  system	  classification	  (62).	  	  Furthermore,	   for	  the	  measurement	  of	  cytokines	  and	  chemokines	  (paper	  1,2	  and	  3)	   a	   commercial	   ELISA	  was	   used	   to	   screen	   the	   blood	   serum	   samples.	   ELISA	   kits	   used	  were	  acquired	  by	  Meso	  Scale	  Discovery®	  (Rockville,	  USA).	  We	  used	  anti-­‐species	  MULTI-­‐ARRAY	   96-­‐well	   plates	   for	   the	   development	   of	   a	   sandwich	   immunoassay.	   The	   10	   spot	  multi-­‐spot	   plates	   were	   pre-­‐coated	   with	   capture	   antibodies	   on	   independent	   and	   well	  defined	   spots	   that	   enabled	   us	   to	   immobilize	   a	   primary	   capture	   antibody	   against	   our	  protein	  of	  interest	  -­‐	  specific	  for	  one	  of	  each	  cytokine.	  	  
	  
1.5. Overview	  on	  results	  and	  achievements	  	  The	   study	   revealed	   differences	   of	   cytokine	   levels	   in	   breast	   cancer	   patients	   of	   the	  SUCCESS	  study	  group	  with	  respect	  to	  CTC	  involvement,	  histopathological	  grading,	  lymph	  node	   status,	   hormone	   receptor	   type,	   TNM	   classification	   and	   survived	   breast	   cancer	  patients	  vs.	  deceased	  tumour	  associated	  patients.	  	  To	  begin	  with,	  as	  described	  in	  Paper	  1,	  the	  distribution	  of	  the	  angiogenic	  markers	  disclosed	  differences	  of	  their	  expression	  in	  breast	  cancer	  patients	  of	  the	  SUCCESS	  study	  group.	  Statistical	  significant	  correlation	  was	  proven	  for	  sFlt1	  values	  regarding	  the	  CTC-­‐status.	   CTC	   negative	   patients	   demonstrated	   enhanced	   sFlt1	   expression	   contrasting	   to	  CTC	  positive	  breast	  cancer	  patients	  (p=0,0034).	  Significant	  enhanced	  PIGF	  values	  were	  additionally	  disclosed	  in	  CTC	  negative	  patients	  compared	  to	  patients	  being	  CTC	  positive	  (p=0,043).	   Amongst	   the	   alive	   patient	   collective,	   significant	   differences	   were	   found	   in	  sFlt1	  (p=0,030)	  and	  PlGF	  (p=0,025)	  values	  regarding	  the	  CTC	  negative	  and	  CTC	  positive	  patient’s	   collective.	   To	   continue,	   the	   collective	   with	   a	   G2	   graded	   tumour	   revealed	  significantly	  increased	  sFlt1	  expressions	  (p=0,041)	  amongst	  the	  patients	  with	  no	  CTCs.	  The	  patient	   collective	  with	  no	   lymph	  node	  metastasis	  and	  CTC	  negativity	   furthermore	  indicated	  statistically	  significant	  enhanced	  sFlt1	  values	  (p=0,039).	  To	   continue,	   also	   amongst	   the	   TH1	   derived	   cytokines	   significant	   differences	   in	  the	  sera	  of	  breast	  cancer	  patients	  with	  and	  without	  circulating	  tumour	  cells	  were	  shown	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(Paper	  2).	  The	  CTC	  positive	  patient	  collective	  implied	  a	  significant	  correlation	  in	  terms	  of	  lymph	  node	  involvement	  concerning	  IL-­‐1α	  (p=	  0,043).	  The	  CTC	  negative	  collective	  on	  the	   other	   hand	   showed	   a	   significant	   difference	   regarding	   progesterone	   receptor	  positive/negative	   patients	   in	   terms	   of	   IL-­‐1β	   (0,029).	   Furthermore,	   the	   living	   patient	  collective	   revealed	   significant	  differences	   in	   IL-­‐12p40	   levels	   in	   regards	   to	   lymph	  node	  involvement	  (p=0,041)	  and	   triple	  negative	  hormone	  receptor	  breast	  cancer	  (p=0,043).	  In	   contrast,	   deceased	   patients	   implied	   significant	   results	   amongst	   the	   oestrogen	  receptor	   positive/negative	   patient	   collective	   regarding	   IL-­‐1α	   (p=0,050)	   and	   IL-­‐1β	  (p=0,034).	   IL-­‐1α	   levels	   furthermore	   indicated	   significant	  differences	   in	   terms	  of	   triple	  negative	   hormone	   receptor	   breast	   cancer	   (p=0,033)	   within	   the	   deceased	   patient	  collective.	  Moreover,	  the	  collective	  graded	  G2	  demonstrated	  significant	  results	  amongst	  patients	  with	  Her2/neu	  association	  regarding	   IFN-­‐γ	   levels	  (p=0,031)	  and	   in	  regards	  to	  lymph	  node	  involvement	  concerning	  IL-­‐1α	  levels	  (p=0,014).	  Tumours	  graded	  with	  G3	  in	  contrast	   exposed	   a	   significant	   correlation	   amongst	   progesterone	   receptor	  positive/negative	   patients	   in	   terms	   of	   IL12p70	   Levels	   (p=0,048)	   and	   triple	   negative	  hormone	  receptor	  breast	  cancer	  regarding	  IL12p40	  levels	  (p=0,033).	  	  Furthermore,	  analysis	  of	  the	  TH2	  derived	  cytokines	  demonstrated	  significant	  levels	  in	   patients	   with	   breast	   cancer	   (Paper	   3).	   The	   CTC-­‐negative	   patient	   collective	   implied	  higher	   expression	   of	   IL-­‐8	   (p=0.017)	   and	   IL-­‐13	   and	   (p=0.045)	   being	   negative	   for	  progesterone	  receptor.	   In	  patients	  who	  died	   tumour	  associated,	  a	  correlation	  between	  hormone	  receptor	  negativity	  and	  enhanced	  IL-­‐4	  levels	  was	  implied.	  IL-­‐4	  levels	  were	  also	  increased	   in	   patients	   with	   progesterone	   receptor-­‐positive	   and	   oestrogen	   receptor-­‐negative	  status	  (p=0.024).	  Moreover,	  IL-­‐5	  levels	  were	  enhanced	  in	  patients	  with	  lymph	  node-­‐positive	  and	  human	  epidermal	  growth	   factor	   receptor	  2	   (HER2)-­‐positive	  disease	  (p=0.042).	   Furthermore,	   the	   IL-­‐6	  was	   significantly	   increased	   in	   patients	   with	   tumour	  grade	  G3	  without	  progesterone	  receptor	  expression.	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1.4	  Contribution	  to	  Publications	  Included	  in	  this	  Thesis	  	  
	  TV	   (Theresa	   Vilsmaier)	   performed	   the	   experiments	   for	   Publications	   1,	   2,	   3	   and	  made	  substantial	   contributions	   to	   acquisition	   and	   interpretation	   of	   data.	   TV	   majorly	  contributed	  to	  data	  analysis,	  completed	  the	  statistical	  work	  and	  drafted	  the	  manuscripts	  for	  the	  Publications	  1,	  2	  and	  3.	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2.	  	   PUBLICATIONS	  INCLUDED	  IN	  THIS	  THESIS	  	  
	  
	   2.1.	  Publication	  1	  
	  
Title:	  	  Angiogenic	  cytokines	  and	  their	  influence	  on	  circulating	  tumour	  cells	  in	  sera	  of	  patients	  with	  the	  primary	  diagnosis	  of	  breast	  cancer	  before	  treatment	  
	  
Authors:	  Theresa	  Vilsmaier,	  Brigitte	  Rack,	  Wolfgang	  Janni,	  Udo	  Jeschke,	  Tobias	  Weissenbacher	  and	  SUCCESS	  Study	  Group	  	  
	  
Journal:	  	  BMC	  Cancer.	  2016	  Jul	  27;16:547.	  doi:	  10.1186/s12885-­‐016-­‐2612-­‐7.	  
	  
Abstract:	  	  
Background:	   Circulating	   tumour	   cells	   (CTCs)	   have	   been	   found	   to	   be	   a	   prognostic	  marker	   for	   reduced	   disease	   free	   survival,	   breast	   cancer–specific	   survival,	   and	   overall	  survival	   before	   the	   start	   of	   systemic	   treatment.	   In	   correspondence	   to	   the	   arising	  significance	   of	   CTC	   involvement	   in	   cancer	   therapy,	   the	   aim	   of	   this	   study	   was	   the	  evaluation	   of	   tumour-­‐angiogenesis	   markers,	   which	   act	   as	   a	   crucial	   factor	   in	   the	  development	  and	  progression	  of	  breast	  cancer,	  in	  association	  to	  CTC	  involvement.	  
Methods:	   Patients	   sera	   chosen	   for	   this	   study	  were	  women	  with	   breast	   cancer	   of	   the	  phase	   I	   SUCCESS	   study.	   CTC	   analysis,	   the	   blood	   sampling	   time	   points,	   and	   the	  methodology	  were	   prospectively	   designed,	   and	   the	   prognostic	   value	   of	   the	   CTCs	  was	  defined	  as	  a	  scientific	  objective	  of	  the	  study	  protocol.	  200	  patients’	  sera	  were	  included	  in	  this	   study,	   100	  patients	   being	  CTC	  positive	   and	  100	  patients	   being	  CTC	  negative.	  One	  patient	   of	   each	   group	  was	   subsequently	  matched	   into	   pairs	   of	   two.	  Matching	   criteria	  were	  histo-­‐pathological	  grading,	  lymph	  node	  metastasis,	  hormone	  receptor	  status,	  TNM	  classification	   and	   survived	   breast	   cancer	   patients	   vs.	   deceased	   tumour	   associated	  patients.	  A	   recently	  developed	  multi	   cytokine/chemokine	  array	   (Meso	  Scale	  Discovery	  ®,	  Rockville,	  USA)	  was	  used	  to	  screen	  the	  sera	  for	  the	  angiogenic	  markers:	  sFlt1,	  PIGF,	  VEGF,	   VEGF-­‐C	   and	   VEGF-­‐D.	   The	   vascular	   markers	   values	   were	   correlated	   to	   the	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matching	  criteria	  and	  analysed	  with	  the	  Spearman	  correlation	  coefficient	  and	  the	  Mann-­‐Whitney-­‐U	  test.	  
Results:	  Statistical	  significant	  correlation	  was	  exposed	  for	  sFlt1	  values	  in	  regard	  to	  the	  CTC-­‐Status.	  CTC	  negative	  patients	  displayed	  increased	  sFlt1	  expression	  opposed	  to	  CTC	  positive	   breast	   cancer	   patients	   (p=0.034).	   Furthermore,	   significant	   enhanced	   PIGF	  values	   were	   also	   disclosed	   in	   CTC	   negative	   patients	   compared	   to	   patients	   being	   CTC	  positive	   (p=0.043).	   Analysing	   the	   living	   patient	   collective	   that	   did	   not	   decease	   breast	  cancer	   associated,	   these	   established	   significant	  differences	   in	   sFlt1	   and	  PlGF	  values	   in	  regard	   to	   CTC	   negative	   and	   CTC	   positive	   patients.	   Both	   vascular	   markers	   showed	  enhanced	   expression	   in	   the	   CTC	   negative	   patient	   collective	   (sFlt1	   p=	   0.030,	   PlGF	  p=0.025).	   To	   continue,	   the	   collective	   graded	   G2	   showed	   significantly	   enhanced	   sFlt1	  expressions	  amongst	  patients	  with	  no	  CTCs	  (p=0.041).	  Moreover,	  the	  patient	  collective	  with	   no	   lymph	   node	   metastasis	   and	   CTC	   negativity	   indicated	   statistically	   significant	  increased	  sFlt1	  values	  (p=0.039).	  	  
Conclusion:	  A	  functional	  interaction	  of	  sFlt1	  and	  PlGF	  was	  found,	  suggesting	  that	  their	  overexpression	   in	   tumour	   cells	   inhibits	   CTCs	   entering	   the	   peripheral	   blood,	   thus	  emphasising	   a	   significant	   anti-­‐angiogenic	   effect,	   inhibiting	   tumour	   growth	   and	  metastasis.	   Furthermore,	   in	   regard	   to	   CTC	   negativity,	   sFlt1	   and	   PlGF	   values	   may	  potentially	  serve	  as	  predictive	  markers.	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RESEARCH ARTICLE Open Access
Angiogenic cytokines and their influence
on circulating tumour cells in sera of
patients with the primary diagnosis of
breast cancer before treatment
Theresa Vilsmaier1, Brigitte Rack1, Wolfgang Janni2, Udo Jeschke1* , Tobias Weissenbacher1 and SUCCESS Study
Group
Abstract
Background: Circulating tumour cells (CTCs) have been found to be a prognostic marker for reduced disease free
survival, breast cancer–specific survival, and overall survival before the start of systemic treatment.
Methods: A total of 200 patients’ sera were included in this study, 100 patients being CTC positive and 100
patients being CTC negative. Matching criteria were histo-pathological grading, lymph node metastasis, hormone
receptor status, TNM classification and survived breast cancer patients vs. deceased tumor associated patients. A
multi cytokine/chemokine array was used to screen the sera for the angiogenic markers.
Results: Statistical significant correlation was exposed for sFlt1 values in regard to the CTC-Status. CTC negative
patients displayed increased sFlt1 expression opposed to CTC positive breast cancer patients. Furthermore,
significant enhanced PIGF values were also disclosed in CTC negative patients compared to patients being CTC
positive. Analyzing the living patient collective we found significant differences in sFlt1 and PlGF values in regard to
CTC negative and CTC positive patients.
Conclusion: Both vascular markers showed enhanced expression in the CTC negative patient collective. To
continue, the collective graded G2 showed significantly enhanced sFlt1 expressions amongst patients with no CTCs.
Moreover, the patient collective with no lymph node metastasis and CTC negativity indicated statistically significant
increased sFlt1 values. A functional interaction of sFlt1 and PlGF was found, suggesting that their overexpression in
tumour cells inhibits CTCs entering the peripheral blood. Furthermore, in regard to CTC negativity, sFlt1 and PlGF
values may potentially serve as predictive markers.
Trial registration: The TRN of this study is NCT02181101 and the date of registration was the 4th of June 2014. The
study was retrospectively registered.
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Background
Worldwide, breast cancer is the most common tumour
diagnosed in women with an estimated 1.7 million new
breast cancer cases and 522,000 breast cancer deaths in
2012 [1]. Whereby, the survival of breast cancer patients
is intensely associated with prognostic factors such as
tumour size, hormone-receptor-profile and presence of
metastases [2]. New approaches have also established a
correlation between poor prognosis and the detection of
Circulating tumour cells (CTCs) before the start of sys-
temic treatment [3]. CTCs in the peripheral blood can be
used as a prognostic marker for reduced disease free-,
breast cancer specific-, and overall- survival before the
start of systemic treatment [3–7]. The detection of CTCs
shortly after commence of therapy even provide comple-
mentary information concerning treatment response [6].
The SUCCESS study was one of the first trials to indicate
the strong prognostic importance, associated with a less
favourable outcome, of CTCs in early breast cancer before
commencing systemic adjuvant treatment and after adju-
vant chemotherapy in a large patient cohort [8].
It is increasingly evident that not only the breast can-
cer cells itself, but also the microenvironment of the
tumour plays a significant role in terms of tumour pro-
gression, metastasis formation and treatment response
[9]. To continue, tumour angiogenesis acts as a crucial
factor in the microenvironment in the development and
progression of breast cancer. In correspondence to the
arising significance of CTC involvement in cancer therapy,
the aim of this study was the evaluation of tumour-
angiogenesis markers in association to CTC involvement.
Furthermore, vascular markers could act as indicators for
the absence or presence of CTCs, as the determination of
CTCs is a time intense and expensive technique.
Neo-angiogenesis, the process of new blood capillary for-
mation from pre-existing vessels, acts as a fundamental part
in both embryonic and postnatal development, in the re-
modelling of various organ structures, and in particular in
tumour growth [10]. Its precarious involvement with
tumour evolution and penetration has already become a
promising focus in cancer therapy [2]. It is implied that
angiogenesis in tumours is part of a multistep progression
including the signalling between breast cancer cells and
several cell types within the tumours microenvironment [2,
10]. A range of pro-angiogenic cytokines, which succumb
an overexpression of factors by the tumour, induces Angio-
genesis [11]. One of the best described is the vascular endo-
thelial growth factor (VEGF). This process of neo-
vascularisation is also referred to as the “angiogenic switch”
[2, 12]. This describes the transition of tumour cells, where
the balance between pro- and anti-angiogenic factors lean
towards pro-angiogenic markers, designating a progression
to an expanding vascularized tumour and eventually to ma-
lignant behaviour [11–13]. Consequently our intention was
to analyse the distribution of angiogenic markers: sFlt1,
PlGF, VEGF, VEGF-C and VEGF-D and disclose the differ-
ences of their expression in breast cancer patients of the
SUCCESS study group in terms of CTC involvement,
histo-pathological grading, lymph node metastasis, hor-
mone receptor status, TNM classification and survived
breast cancer patients vs. deceased tumour associated pa-
tients. A Sandwich immunoassay ELISA and anti-species
Multi-Array 96 well plates were used to screen the blood
serum samples that enabled us to screen for all mentioned
vascular markers in just one well at the same time.
The cytokines belonging to the vascular endothelial
growth factor (VEGF) family and its important involve-
ment in angiogenesis have been subject of major interest.
The VEGF family includes six related gene members;
VEGF, VEGF-B, VEGF-C, VEGF-D, VEGF-F and placental
growth factor (PIGF) that are regulators of angiogenesis
or lymphangiogenesis or of both processes [2, 11, 14]. To
continue, the markers have been described to bind with
diverse affinity to one of the three tyrosine kinase recep-
tors known as vascular endothelial growth factor receptor
VEGFR-1 (sFlt1), VEGFR-2 and VEGFR-3 [15–17], initiat-
ing a signalling cascade promoting survival, growth and
migration of tumour cells [2, 18]. Increased levels of
VEGF in tumour patients have been described as a well-
established indicator of poor prognosis [19]. PIGF and
sFlt1 on the other hand have been known to play a major
role in preeclampsia, and even associated with a lower
breast cancer risk later in life of those patients [20, 21].
In conclusion, the assessment of vascular tumour angio-
genesis markers in relationship to CTC involvement and
the expression of angiogenesis markers in terms of histo-
pathological grading, lymph node involvement, hormone
receptor status, TNM classification and survived breast
cancer patients vs. deceased tumour associated patients,
could found an advantage in regard to assessing the
discrete risk of patients at the time of primary diagnosis.
The assessment of the angiogenesis factors in patients
with different phenotype breast cancer, could furthermore
allow a profounder understanding of how angiogenesis-
related genes may influence breast carcinogenesis, thus
allowing an increased enhanced individualized treatment.
Methods
Study design and ethical board permission
Eligible patients were defined as women with breast
cancer (stages pT1–T4, pN0–N3, M0) who accepted to
participate in the phase I SUCCESS study (www.su
ccess-studie.de). SUCCESS was a prospective, random-
ized adjuvant study comparing three cycles of fluorouracil-
epirubicin-cyclo-phosphamide (FEC; 500/100/500 mg/m2)
followed by 3 cycles of docetaxel (100 mg/m2) every
3 weeks vs. three cycles of FEC followed by 3 cycles of gem-
citabine (1000 mg/m2 d1,8)-docetaxel (75 mg/m2) each
Vilsmaier et al. BMC Cancer  (2016) 16:547 Page 2 of 11
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3 weeks. After the completion of chemotherapy, the pa-
tients were furthermore randomized to receive either 2 or
5 years of zoledronate. Hormone receptor–positive women
moreover received suitable endocrine treatment. The re-
search questions related to CTC analysis, the blood sam-
pling time points, and the methodology were prospectively
designed, and the prognostic value of the CTCs was de-
scribed as a scientific objective of the study protocol. The
study was permitted by 37 German ethical boards (lead eth-
ical board: LMU, Munich) and conducted in agreement
with the Declaration of Helsinki.
Blood samples for CTC enumeration were collected
from 2090 consecutive patients after complete resection
of the primary tumour and before adjuvant chemother-
apy after written informed consent was acquired. Never-
theless, sixty-four patients were disqualified because of
test failure or a time intermission of more than 96 h
between the blood collection and sample preparation. A
follow-up evaluation after chemotherapy and before the
beginning of endocrine or bisphosphonate treatment
was available for a subgroup of 1492 patients (see home
page: http://www.success-studie.de).
Patients
In this study 200 Patients of the SUCCESS study were
incorporated and assigned into two groups: 100 Pa-
tients were CTC positive (Group 1. CTC Positive) and
the other 100 Patients were CTC negative (Group 2.
CTC Negative). These two groups were then framed
and investigated correspondingly. Patients from re-
spectively groups were then matched into pairs of two
rendering to histo-pathological grading, lymph node
involvement, hormone receptor type, TNM classifica-
tion and survived patients vs. deceased patients breast
cancer associated. The 200 patient samples that were
investigated contained 160 patients that were still alive
at last observation after end of therapy and 40 patients
that had deceased during therapy tumour associated.
Furthermore, the groups considered contained 98 pa-
tients graded G2 and 102 patients graded G3. Matching
criteria of the 200 breast cancer patients did not allow
patients graded G1. Tumour stage of the anamnestic diag-
nosis was categorised according to the TNM-classification,
which was conducted correspondingly to the WHO Sys-
tem [22]. The matching of patients was executed accord-
ing to the criteria at the time of primary diagnosis. The
histo-pathological grading was classified conferring to the
Bloom and Richardson system classification [23].
Collection of blood samples and Detection of CTCs
Method was conducted as defined by the SUCCESS
Study group [8]. CTCs were examined using the Cell-
Search System (Veridex, Raritan, NJ). Peripheral blood
was drawn into three CellSave tubes (3x10 mL – Serum
Vacutainer from BD Ref. Nr. 367896), sent at room
temperature to the central laboratory at the University of
Munich, and inspected within 96 h of collection. Conse-
quently, the patient sera was frozen at −80 °C and seasoned
in Nitrogen for long-term storage.
The patient blood samples were then centrifuged for
10 min at 800 × g. The plasma was removed, and a dilution
buffer was added. This arrangement was overlaid on 6 mL
of Histopaque (Sigma, Steinheim, Germany) and centri-
fuged for 10 min at 400 × g. Subsequently, 7.5 mL of this
sample enclosing the buffy coat was treated on the Cell-
Tracks AutoPrep system using the CellSearch Epithelial Cell
Kit (Veridex). After immuno-magnetic enrichment with an
anti-Epcam antibody, the cells were marked with fluores-
cent anticytokeratin (CK8, 18, 19–phycoerythrin) and anti-
CD45 antibodies (CD45–allophycocyan), and 4,6-diami
dino-2-phenylindoledihy-drochloride was used to classify
the intact cells.
The identification, documentation and enumeration of
CTCs were achieved using the CellTracks Analyzer II. CTCs
were stated as nucleated cells lacking CD45 and expressing
cytokeratin. Two independent investigators assessed all posi-
tive samples. The samples with a minimum of one CTC per
30 mL of blood were considered as CTC positive.
Measurement of cytokines
ELISA was performed with recently developed multi cyto-
kine/chemokine arrays (Meso Scale Discovery®, Rockville,
USA) to screen the blood serum samples for the vascular
markers sFlt1, PIGF, VEGF, VEGF-C and VEGF-D. The
immunoassays were commercially available. We used anti-
species MULTI-ARRAY 96-well plates for the develop-
ment of a sandwich immunoassay. Each assay in the panel
was verified individually for the Specificity by running
single calibrator with single detection antibodies. Non-
specific binding levels were less than 0.5 % for all assays.
The 10 spot MULTI-SPOT plates were pre-coated with
capture antibodies on independent and well defined spots
that allowed us to immobilize a primary capture antibody
against our protein of interest - specific for one of each
vascular marker. Standards and samples were added to the
appropriate wells. A standard curve was furthermore run
with each assay. We firstly added the blood serum,
calibrator and control. After that we incubated at room
temperature with shaking for 2 h. After eliminating excess
samples from the well with wash buffer, we added a solu-
tion containing the detection (anti-target) antibody conju-
gated with electrochemiluminescent labels over the course
of two incubation periods. During incubation time, where
time slots differed in each test, the target present in the
sample bound to the capture antibody immobilized on the
working electrode surface by the anti-species antibody. Re-
cruitment of the labelled detection antibody by the bound
target completed the sandwich. After a second shaking
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incubation period (time differed for each test) wash buffer
was used to eliminate the entire unbound enzymes and a
MSD Read Buffer was added to produce the suitable
chemical environment for electrochemiluminescence. We
then loaded the plate into an MSD instrument (MESO
QuickPlex SQ 120) for examination where voltage applied
to the plate electrodes caused the captured labels to emit
light. The instrument calculated the intensity of the emit-
ted light to present a quantitative measure of the amount
of the protein of interest that was present in the sample
[24, 25] (see homepage: www.mesoscale.com).
Statistical analysis
Statistical analysis was implemented using SPSS 22.0
(SPSS Inc., IBM, Chicago, IL). The outcomes collected
were recorded and inserted into the SPSS database in
the implied manner. We evaluated the relationship be-
tween each vascular marker: sFlt1, PIGF, VEGF, VEGF-C
and VEGF-D and each matching criteria (1. CTC-
Positive vs. CTC-Negative, 2. Patient survived vs. Patient
deceased, 3. Grading G2 vs. Grading G3, 4. Lymph node
involvement vs. No lymph node involvement, 5. Triple
positive vs. Triple negative 6. Progesterone receptor-
positive vs. Progesterone receptor-negative, 7. Oestrogen
receptor-positive vs. Oestrogen receptor-negative, 8. Her
2/neu receptor-positive vs. Her 2/neu receptor-negative)
in the total patient collective and also regarding each
matching criteria alone, by the use of the non-parametric
Spearman correlation coefficient. Each parameter to be
considered needed to have a p value <0.50. Statistical sig-
nificant results within the Spearman correlation coefficient
were then additionally assessed with the non-parametric
Mann-Whitney-U-test. Moreover, variables were scruti-
nized by the use of Box-Plot analysis. All statistical tests
were considered significant at p < 0.05.
Results
CTC positive vs. CTC negative
In the total patient collective, statistical significant differ-
ences were shown for sFlt1 values in regard to the CTC-
Status. Box-plot analysis revealed that CTC negative
patients exposed increased sFlt1 expression opposed to
the CTC positive breast cancer patients that showed
decreased sFlt1 values. The spearman correlation coeffi-
cient assessed the p-value of 0.034, additionally sup-
ported by the Mann-Whitney-U-Test p = 0.034, proving
a significant correlation between CTC-status and sFlt1.
In addition, ROC analysis was performed, exposing an
AUC value of 0.413 (see Fig. 1a).
Furthermore, a statistical significant correlation was
found for PIGF values concerning the CTC-status. Box-
plot analysis identified significant enhanced PIGF values
in CTC negative patients compared to patients being CTC
positive. The spearman correlation coefficient assessed the
p-value of 0.043 which was moreover supported by the
Mann-Whitney-U-Test p = 0.043. ROC analysis imple-
mented an AUC value of 0.417. (see Fig. 1b).
Nevertheless, the statistical analysis confirmed no sig-
nificant correlation in terms of the CTC-Status regard-
ing the vascular markers VEGF, VEGF-C, VEGF-D.
Patient survived vs. patient deceased
Analysing the patient collective who were still alive, and
did not decease breast cancer associated, these showed
statistically significant differences between CTC negative
and CTC positive patients in terms of the vascular
marker sFlt1. The box-plot analysis revealed that the
survived patients collective who were CTC negative dis-
play higher levels of sFlt1 compared to the reduced
values of sFlt1 in the survived patients with the presence
of CTCs. The spearman correlation coefficient assessed
the p-value of 0.030 which was additionally supported by
the Mann-Whitney-U-Test p = 0.030. To continue, ROC
analysis was performed, displaying an AUC value of
0.401 (see Fig. 2a).
Moreover, a statistical significant correlation was also
proven for survived breast cancer patients being either
CTC negative or CTC positive in respect to the vascular
marker PIGF. The box-plot analysis disclosed that the
survived patients collective who were CTC negative
demonstrate increased PIGF expression in comparison
to the decreased PIGF values in the survived patients
being CTC positive. The spearman correlation coeffi-
cient evaluated the p-value of 0.025 which was further-
more reinforced by the Mann-Whitney-U-Test p = 0.026.
ROC analysis was executed, revealing an AUC value of
0.398 (see Fig. 2b).
However, the statistical analysis verified no significant
correlation in the survived patient collective regarding
the vascular markers VEGF, VEGF-C, VEGF-D. To con-
clude, statistical analysis also demonstrated no signifi-
cant differences concerning the deceased patients who
had died breast cancer associated, with and without the
presence of CTCs, in respect to the vascular markers
sFlt1, PIGF, VEGF, VEGF-C and VEGF-D.
Lymph node involvement vs. no lymph node involvement
The patient collective with no lymph node metastasis in-
dicated statistically significant differences between CTC
negative and CTC positive breast cancer patients in re-
gard to the vascular marker sFlt1. Box-plot analysis
exposed that patients with no lymph node metastasis
and CTC negativity demonstrated increased sFlt1 values
in contrast to the reduced sFlt1 levels in patients with
no lymph node metastasis and CTC positivity. The
spearman correlation coefficient calculated the p-value
of 0.039 which was furthermore sustained by the Mann-
Vilsmaier et al. BMC Cancer  (2016) 16:547 Page 4 of 11
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Whitney-U-Test p = 0.041. ROC analysis assessed the
AUC value of 0.350 (see Fig. 3a).
Nonetheless, statistical analysis demonstrated no sig-
nificant correlation concerning patients without lymph
node involvement in respect to the vascular markers
PIGF, VEGF, VEGF-C and VEGF-D. Furthermore, pa-
tients with lymph node metastasis, with and without the
presence of CTCs, displayed no significant difference in
respect to the vascular markers sFlt1, PIGF, VEGF, VEGF-
C and VEGF-D.
Grading G2 vs. Grading G3
The collective graded G2 showed significant correlations
amongst patients with the presence or absence of CTCs
in terms of the vascular marker sFlt1. The box-plot ana-
lysis identified that patients graded with a G2 breast
cancer and furthermore being negative for CTCs display
higher levels of sFlt1 in comparison to the decreased
values of sFlt1 in G2 graded breast cancer with the
presence of CTCs. The spearman correlation coefficient
evaluated the p-value of 0.041 which was additionally
Fig. 1 a: Box plot analysis of sFLT1 expression in sera of breast cancer patients. We identified a significant enhanced sFLT1 release in CTC
negative patients compared to patients being CTC positive p = 0.034. In addition ROC analysis was performed. AUC value is 0.413. b: Box plot
analysis of PlGF expression in sera of breast cancer patients. We identified a significant enhanced PlGF values in CTC negative patients compared
to patients being CTC positive p = 0.043. In addition ROC analysis was performed. AUC value is 0.417
Vilsmaier et al. BMC Cancer  (2016) 16:547 Page 5 of 11
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sustained by the Mann-Whitney-U-Test p = 0.042. To
continue, ROC analysis was performed, revealing an
AUC value of 0.381 (see Fig. 4a). None of the other
vascular markers tested revealed differences in expres-
sion patterns in terms of Grading.
Hormone receptor type presence vs. absence
Furthermore, the statistical analysis also verified no sig-
nificant correlation regarding the presence or absence of
each single hormone receptor type; Progesterone recep-
tor, oestrogen receptor, Her2/neu, in patients with breast
cancer with and without the presence of CTCs, with re-
spect to the vascular markers sFlt1, PIGF, VEGF, VEGF-
C and VEGF-D.
Triple positive vs. triple negative
Moreover, no statistically significant correlation could be
demonstrated with the general comparison of a triple
negative hormone receptor to a triple positive breast
cancer with and without the presence of CTCs in terms
of the vascular markers sFlt1, PIGF, VEGF, VEGF-C and
VEGF-D.
Fig. 2 a: Box plot analysis of sFLT1 expression in sera of breast cancer patients who survived. We identified significant enhanced sFLT1 release in
the survived patient collective and patients being CTC negative p = 0.030. In addition ROC analysis was performed. AUC value is 0.401. b: Box plot
analysis of PlGF expression in sera of breast cancer patients who survived. We identified significant enhanced PlGF release in the survived patient
collective and patients being CTC negative p = 0.026. In addition ROC analysis was performed. AUC value is 0.398
Vilsmaier et al. BMC Cancer  (2016) 16:547 Page 6 of 11
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Vascular marker correlation
Significant correlation could be validated with the
spearman correlation coefficient for the association be-
tween the vascular markers itself. The vascular markers
examined were sFlt1, PIGF, VEGF, VEGF-C and VEGF-
D. In regard to the total patient collective, with and with-
out the presence of CTCs, significant correlations were
found between sFlt1 and PIGF (p = 0.000066), sFlt1 and
VEGF-C (p = 0.022), PIGF and VEGF (p = 0.038), VEGF
and VEGF-C (p = 0.045), VEGF-C and VEGF-D (p =
0.0000001) (see Fig. 5).
Discussion
Within this study we analysed the distribution of angio-
genic markers: sFlt1, PIGF, VEGF, VEGF-C and VEGF-D
and reveal the differences of their expression in the sera
of breast cancer patients with and without circulating
tumour cells. Significantly enhanced sFlt1 values were
Fig. 3 Box plot analysis of sFLT1 expression in sera of breast cancer patients with no lymph node metastasis. We identified significant enhanced
sFLT1 release in the patient collective with no lymph node involvement and CTC negativity p = 0.041. In addition ROC analysis was performed.
AUC value is 0.350
Fig. 4 Box plot analysis of sFLT1 expression in sera of breast cancer patients with a G2 graded tumour. We identified significant enhanced sFLT1
release in the G2 graded patient collective and CTC negativity p = 0.042. In addition ROC analysis was performed. AUC value is 0.381
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shown for the group of patients diagnosed with no
CTCs. It is implied that sFlt1, which is the extra-cellular
soluble domain of the VEGF receptor 1 (VEGFR1), traps
VEGF thus acting as an important factor in the negative
down regulation of angiogenesis [26, 27]. Furthermore,
sFlt1 is described as an inhibiting factor of the pro-
angiogenic VEGFR2 that acts as a positive signal con-
ductor, whereas VEGFR-1 is a suppressor of VEGFR-2 sig-
nalling, consequently decreasing the neo-vascularisation
stimulus [27, 28]. The tumour growth and the develop-
ment of an invasive, aggressive and metastatic breast can-
cer are essentially reliant on the neo-vascularisation to
provide blood supply for the nourishment and growth of
the tumour. One can consequently suggest that the in-
creased sFlt1 values in the CTC negative collective cause a
significant disruption of tumour vascularisation, inhibiting
CTCs being released into the peripheral blood. One could
also suggest a significant additive inhibition delay in
tumour growth, explaining and ensuing in the absence of
CTCs in those patients.
This hypothesis is furthermore supported by increased
levels of sFlt1 in the sera of the survived breast cancer
patient collective and no CTC involvement. The ability
of sFlt1 to bind and neutralize its target as it moves
through the interstitial matrix is mostly described for
one of the greatest powerful regulatory angiogenic agent
VEGF [29, 30]. The role of sFlt1 has been previously
shown to exercise a favourable outcome and advanced
therapeutic effect in several tumour models [31]. There-
fore, sFlt1 might have a major impact on anti-angiogenic
activity by the requisitioning and neutralization of
tumour secreted pro-angiogenic factors such as VEGF.
This angiogenic inhibition might therefore contribute to
slower and decreased tumour growth, inhibiting circula-
tion specific metastasis, thus enhancing survival and
resulting in a favourable conduct of those breast cancer
patients.
To continue, the group of patients with no lymph
node metastasis and no CTC involvement in the periph-
eral blood also indicated significantly enhanced sFlt1
expression. It is hypothesized that sFlt1 inhibits endo-
thelial cell proliferation and sprouting in the tumours
microenvironment, resulting in a decrease of the total num-
ber of tumour blood vessels, as well as the number of per-
fused vessels, demonstrating a combined anti-tumour and
anti-vascular effect [9, 28]. The tumours microenvironment
in association to sFlt1 values might therefore benefit from
its anti-angiogenic effects by successfully inhibiting lym-
phangiogenesis. One can consequently suggest that sFlt1
not only acts as an important factor in terms of down regu-
lating neo-vascularisation hence decreasing tumour pro-
gression, but also influences lymph metastasis formation in
favour of patient outcome.
Furthermore, in the sera of breast cancer patients
with a G2 histologically graded tumour and CTC nega-
tivity, showed significantly enhanced sFlt1 expression.
It is implicated that sFlt1 leads to a significant delay in
tumour growth without altering the revascularization of
ischemic peripheral tissue [26, 32]. Also, sFlt1 presum-
ably does not directly control growth of the malignant
tumour cells but is linked with a more favourable out-
come through the restriction of tumour vascularization
[33]. Therefore, significantly enhanced sFlt1 expressions
in CTC negative patients indicate a correlation with
medium differentiated (G2) breast cancer patients and
resulting in a favourable breast cancer manner.
Fig. 5 Spearman correlation of vascular markers: sFlt1, PIGF, VEGF, VEGF-C and VEGF-D. In regard to the total patient collective, significant correlation
was found between: sFlt1 and PIGF (p = 0.000066), sFlt1 and VEGF-C (p = 0.022), PIGF and VEGF (p = 0.038), VEGF and VEGF-C (p = 0.045) and VEGF-C
and VEGF-D (p = 0.0000001)
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Similarly to the sFlt1 values pattern, significantly en-
hanced Placental growth factor (PlGF) values were shown
for the group of patients diagnosed with no CTCs in con-
trast to CTC positive breast cancer patients. Furthermore,
increased levels of PlGF were also proven in the sera of
the survived breast cancer patient collective and no CTC
involvement. sFlt1 and PlGF values therefore correlate in
these patient collectives, both showing enhanced values.
PlGF also belongs to the VEGF family, which exclu-
sively binds to the sFlt1 receptor (VEGFR1) [34]. The
association between PlGF and sFlt1 has already been
established, especially in terms of preeclampsia. Placen-
tal production of sFlt1 is increased during preeclampsia
[35, 36], whereas PlGF and VEGF are decreased during
active disease and several weeks before commencement
of symptoms [37]. sFlt1 hereby acts as a potent anti-
angiogenic factor, binding and neutralizing the pro-
angiogenic proteins VEGF and PlGF, playing a key role
in the inhibition of placental angiogenesis [38]. Never-
theless, the role of PlGF in terms of tumour angiogenesis
and tumour growth remains controversial. Some studies
claim that PlGF promotes tumour angiogenesis and
tumour growth [39–41], although numerous other ana-
lyses indicated that overexpression of PlGF in tumour
cells suppresses tumour neovascularization and growth
[42–47]. Research implies that in addition to forming
homodimers, PlGF and VEGF can also form heterodi-
mers that contrary to prior evidence may be inactive and
function as inhibitors of tumour angiogenesis [11, 43,
48]. Therefore, PlGF may negatively modulate VEGF-
induced angiogenesis by formation of biologically in-
active heterodimers [43, 46, 49]. It is furthermore im-
plied that PlGF in tumours significantly normalizes
tumour vessels against vascular leakage, whereas block-
ing sFlt1 leads to an increased vascular leakage, thus
causing a less favourable outcome [47]. Our results in
terms of enhanced PlGF values in the CTC negative pa-
tient collective and furthermore in the survived breast
cancer patient collective and no CTC involvement sup-
ports the implication that tumour derived PlGF nega-
tively modulates tumour angiogenesis and tumour
growth [47]. This hypothesis if furthermore supported
by the increased levels of sFlt1 in these patient collec-
tives as it is presumed that PlGF stimulates the prolifera-
tion of cell types that express sFlt1 [50]. Therefore one
can suggest that the tumour derived PlGF in our breast
cancer patients suppresses tumour angiogenesis, tumour
growth and metastasis by a probable mechanism includ-
ing PlGF homodimers or PlGF–VEGF heterodimers, ac-
tivating a negative neovascularisation feedback via sFlt1
activation. Moreover, this hypothesis is reinforced by the
significant correlations amongst the vascular markers. Sig-
nificant correlation between sFlt1 and PlGF emphasize their
association as well as the significant correlation between
PlGF and VEGF, implying the presence of PlGF-VEGF
heterodimers.
These findings demonstrate the functional interaction
of sFlt1 and PlGF, suggesting that their overexpression
in tumour cells inhibits CTCs entering the peripheral
blood, thus emphasising a significant anti-angiogenic ef-
fect, inhibiting tumour growth and metastasis. Further-
more, in regard to CTC negativity, sFlt1 and PlGF values
may potentially serve as predictive markers.
Conclusion
Circulating tumour cells (CTCs) are a prognostic marker
for reduced disease free survival, breast cancer–specific
survival, and overall survival. CTC negative patients dis-
played increased sFlt1 expression opposed to CTC posi-
tive breast cancer patients. Furthermore, significant
enhanced PIGF values were also disclosed in CTC nega-
tive patients compared to patients being CTC positive.
In former studies, a functional interaction of sFlt1 and
PlGF was found. Results of our study suggest that their
overexpression in tumour cells inhibits CTCs entering
the peripheral blood. Furthermore, in regard to CTC
negativity, sFlt1 and PlGF values may potentially serve
as predictive markers.
Abbreviations
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endothelial growth factor
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Abstract:	  	  
Background:	   Circulating	   tumour	   cells	   (CTCs)	   have	   been	   found	   to	   be	   a	   prognostic	  marker	   for	   reduced	   disease	   free	   survival	   (DFS),	   distant	   DFS,	   breast	   cancer–specific	  survival,	  and	  overall	  survival	  (OS)	  before	  the	  start	  of	  systemic	  treatment.	  Determination	  of	   CTCs	   with	   the	   CellSearch	   System	   (Veridex,	   Raritan,	   NJ)	   is	   a	   valuable	   but	   time	  consuming	   and	   costly	  method.	   Therefore	   the	   aim	   of	   this	   study	  was	   the	   evaluation	   of	  cytokine	  profiles	  as	  marker	  for	  CTC	  involvement.	  
Methods:	  Patients	  chosen	  for	  this	  study	  were	  defined	  as	  women	  with	  breast	  cancer	  who	  agreed	   to	   participate	   in	   the	   phase	   I	   SUCCESS	   study.	   CTC	   analysis,	   the	   blood	   sampling	  time	  points,	  and	  the	  methodology	  were	  prospectively	  designed,	  and	  the	  prognostic	  value	  of	   the	  CTCs	  was	  defined	  as	   a	   scientific	   objective	  of	   the	   study	  protocol.	   	  A	   total	   of	   100	  patients	   being	   positive	   for	   circulating	   tumour	   cells	   and	   additional	   100	   patients	   being	  negative	  for	  circulating	  tumour	  cells	  were	  matched	  into	  pairs	  of	  two.	  Matching	  criteria	  were	   histo-­‐pathological	   grading,	   lymph	   node	   status,	   hormone	   receptor	   type,	   TNM	  classification	   and	   survived	   breast	   cancer	   patients	   vs.	   deceased	   tumour	   associated	  patients.	   Commercial	  ELISA	  was	  used	   to	   screen	   the	  blood	   serum	  samples	   for	   the	  TH1	  cytokines:	   IFN-­‐γ,	   TNF-­‐α,	   IL-­‐12,	   IL-­‐1α,	   IL-­‐1b,	  	   IL-­‐2	   and	   IL-­‐18.	   The	   cytokine	   levels	  correlation	   to	   the	   matching	   criteria	   listed	   above	   was	   analysed	   with	   the	   Spearman	  correlation	  coefficient	  and	  the	  Mann-­‐Whitney-­‐U	  rank-­‐sum	  test.	  
Results:	  CTC	  positive	  patient	  group	  indicated	  a	  significant	  difference	  in	  terms	  of	  lymph	  node	   involvement	   regarding	   IL-­‐1α	   (p=0,043).	   The	   CTC	   negative	   collective	   exposed	   a	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significant	   correlation	   regarding	   progesterone	   receptor	   positive/negative	   patients	   in	  terms	   of	   IL-­‐1β	   (p=0,029).	   Furthermore,	   the	   living	   patient	   collective	   established	  significant	   differences	   in	   IL-­‐12p40	   levels	   in	   association	   to	   lymph	   node	   involvement	  (p=0,041)	   and	   triple	   negative	   hormone	   receptor	   breast	   cancer	   (p=0,043).	   Deceased	  patients	   on	   the	   other	   hand	   presented	   significant	   results	   within	   oestrogen	   receptor	  positive/negative	  patients	   in	   terms	  of	   IL-­‐1α	  (p=0,050)	  and	  IL-­‐1β	  (p=0,034).	  Moreover,	  IL-­‐1α	   levels	   also	   indicated	   a	   significant	   correlation	   regarding	   triple	   negative	   hormone	  receptor	   breast	   cancer	   (p=0,033)	   within	   the	   deceased	   collective.	   To	   continue,	   the	  collective	   graded	  G2	   showed	   significant	   correlations	   amongst	   patients	  with	  Her2/neu	  association	   regarding	   IFN-­‐γ	   levels	   (p=0,031)	   and	   in	   terms	  of	   lymph	  node	   involvement	  concerning	  IL-­‐1α	  levels	  (p=0,014).	  The	  patient	  group	  graded	  with	  G3	  on	  the	  other	  hand	  revealed	   a	   significant	   correlation	   regarding	   progesterone	   receptor	   positive/negative	  patients	   in	   terms	   of	   IL12p70	   Levels	   (p=0,048)	   and	   triple	   negative	   hormone	   receptor	  breast	  cancer	  with	  regard	  to	  IL12p40	  levels	  (p=0,033).	  	  
Conclusion:	   Regarding	   CTC	   involvement	   we	   found	   significant	   differences	   in	   IL-­‐1α	  secretion	  in	  CTC	  positive	  patients.	  Increased	  values	  of	  this	  cytokine	  were	  found	  in	  sera	  of	   patients	   without	   lymph	   node	   involvement.	   Therefore	   we	  may	   speculate	   that	   IL-­‐1a	  might	   be	   a	  marker	   for	   the	   release	   of	   tumour	   cells	   into	   the	   circulation	   and	   not	   in	   the	  lymphatic	  system.	  In	  addition,	  also	  Il-­‐1b	  was	  found	  to	  correlate	  to	  CTC	  release.	  Only	  CTC	  negative	  patients	  showed	  a	  correlation	  of	  the	  progesterone	  receptor	  expression	  and	  Il-­‐1b	  release.	   	  Therefore	  we	  conclude	  that	  as	  well	  as	  IL-­‐1a	  as	  IL-­‐1b	  are	  connected	  to	  CTC	  release	  of	  breast	  cancer	  patients.	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Abstract. Background: Circulating tumour cells (CTCs)
have been found to be a prognostic marker for reduced
disease-free survival (DFS), distant DFS, breast cancer-
specific survival, and overall survival (OS) before the start
of systemic treatment. Determination of CTCs with the
CellSearch System (Veridex, Raritan, NJ, USA) is a valuable
but time-consuming and costly method. Therefore, the aim of
this study was to evaluate cytokine profiles as a marker for
CTC involvement. Patients and Methods: Patients chosen for
this study were defined as women with breast cancer who
agreed to participate in the phase I SUCCESS study. CTC
analysis, the blood sampling time points, and the
methodology were prospectively designed, and the prognostic
value of the CTCs was defined as a scientific objective of the
study protocol. A total of 100 patients positive for CTCs and
an additional 100 patients negative for CTCs were matched
into pairs. Matching criteria were histopathological grading,
lymph node status, hormone receptor type, TNM
classification and survival vs. tumour associated death.
Commercial enzyme-linked immunosorbent assay (ELISA)
was used to screen the blood serum samples for the Th1
cytokines: interferon gamma (IFN-γ), tumor necrosis factor
alpha (TNF-α), interleukin 12 (IL-12), IL-1α, IL-1β, IL-2
and IL-18. The correlation of cytokine levels to the matching
criteria listed above were analyzed with the Spearman
correlation coefficient and the Mann–Whitney-U rank-sum
test. Results: The IL-1α level was significantly lower in the
CTC-positive patient group (p=0.043) but significantly
higher in the CTC-negative progesterone receptor-positive
collective (p=0.029). Furthermore, in patients who survived,
significantly higher IL-12p40 levels were found in those with
lymph node involvement (p=0.041) and those with triple-
negative breast cancer (p=0.043). Of patients who died,
those with oestrogen receptor-negative disease had higher
IL-1α (p=0.050) and higher IL-1β (p=0.034) levels.
Moreover, of those who died, those with triple-negative
breast cancer had significantly higher IL-1α levels
(p=0.033). In patients with grade 2 tumour, patients with
HER2/neu expression had significantly higher IFN-γ levels
(p=0.031) and those with no lymph node involvement had
significantly higher IL-1α levels (p=0.014). In the collective
with grade 3 tumour, patients with progesterone receptor-
negative disease had significantly higher IL12p70
concentrations (p=0.048), while those with triple-negative
breast cancer had lower IL12p40 levels (p=0.033).
Conclusion: Regarding CTC involvement, we speculate that
IL-1α might be a marker for the release of tumour cells into
the circulation and not into the lymphatic system. In
addition, IL-1α like IL-1β appears to be related to CTC
release in patients with breast cancer.
Analyses with the highest level of evidence have established
a correlation between poor prognosis and the detection of
circulating tumour cells (CTCs) before the start of systemic
treatment (1). CTCs in the peripheral blood have been found
to be a prognostic marker for reduced disease-free survival
(DFS), distant DFS, breast cancer–specific survival, and
overall survival (OS) before the start of systemic treatment
(1-5). Furthermore, CTC values shortly after commencing
therapy provide complementary information concerning the
treatment response (5). The SUCCESS study was one of the
first trials to determine the strong prognostic association of
CTCs with poorer survival in early breast cancer before the
start of systemic adjuvant treatment and after adjuvant
chemotherapy in a large patient cohort (6). 
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Nevertheless, the determination of CTCs is time-
consuming and costly. Given the increasing significance of
cytokine measurement in cancer therapy, the aim of this
study was the evaluation of cytokine profiles as a marker for
CTC involvement.
T-Lymphocytes and their individual differentiation
depending on cytokines and chemokines are a crucial
component of the adaptive immune response, presumed to
be an important prognostic factor in the presence of breast
cancer tumours (7). The differential expression of cytokines
that stimulate helper T-lymphocyte maturation can result in
stimulation or suppression of critical cell derivation (8, 9).
Different interactions lead to the expression of either pro-
inflammatory or anti-inflammatory cytokines (10). Therefore
our intention was to analyse the distribution of T-helper 1
(Th1), Th2, Th17, regulatory T-cells (Treg) and Th9
cytokines of the T-lymphocyte immune response and reveal
differences in cytokine levels in patients with breast cancer
of the SUCCESS study group. We studied this with respect
to CTC involvement, histopathological grading, lymph node
status, hormone receptor type, TNM classification and
survival vs. tumour-associated death. 
This article focuses on the expression of the Th1
cytokines: Interferon gamma (IFN-γ), tumour necrosis factor
alpha (TNF-α), interleukin 12 (IL-12), IL-1α, IL-1β, IL-2
and IL-18. Th1 cytokines have been presumed to play a
major role in phagocytic and intracellular defence (8).
Analyses imply that patients with breast cancer present
specific Th1 expressions that correlate with TNM stage and
lymph node involvement. Higher IFN-γ values, for instance,
correlated with a positive outcome in patients with breast
cancer (11), whereas the presence of the IL-1 system was
found to correlate inversely with local sex steroid receptor
expression, emphasizing a increased malignant behaviour
(12). Moreover, IL-12 is assumed to be one of the most
critical cytokines for the induction of Th1 responses (8).
The evaluation of TH1 cytokine profiles as a marker for
CTC involvement could benefit assessment of the individual
risk of patients at the time of primary diagnosis. Correlation
of Th1 cytokines to CTC involvement could offer a new
clinical prospective in terms of tumour phenotype in order
to enhance individualized treatments. 
Materials and Methods
SUCCESS study design. SUCCESS was a prospective, randomized
adjuvant study comparing three cycles of fluorouracil–epirubicin–
cyclophosphamide (FEC; 500/100/500 mg/m2) followed by three
cycles of docetaxel (100 mg/m2) every 3 weeks vs. three cycles of
FEC followed by three cycles of gemcitabine (1,000 mg/m2 d1,8)
docetaxel (75 mg/m2) every 3 weeks. Following the completion of
chemotherapy, the patients were further randomized to receive either
2 or 5 years of bisphosphonate therapy with zoledronate. Hormone
receptor-positive women received suitable endocrine treatment.
Eligible patients were defined as women with breast cancer (stages
pT1–T4, pN0–N3, M0) who were approved to participate in the
phase I SUCCESS study (www.success-studie.de).
The research questions associated with CTC analysis, the blood
sampling time points, and the methodology were prospectively
designed, and the prognostic value of the CTCs was described as a
scientific objective of the study protocol. The study was permitted
by 37 German ethical boards (lead ethical board: LMU, Munich)
and conducted in agreement with the Declaration of Helsinki. 
Blood sample collection for CTC enumeration. Blood samples for
CTC enumeration were taken from 2,090 consecutive patients after
complete resection of the primary tumour and before adjuvant
chemotherapy after written informed consent was acquired. Sixty-
four patients were excluded because of test failure or a time interval
of more than 96 h between the blood collection and sample
preparation. A follow-up evaluation after chemotherapy and before
the commencement of endocrine or bisphosphonate treatment was
available for a subgroup of 1,492 patients (see homepage:
http://www.success-studie.de).
The method was conducted as described by the SUCCESS Study
group (6). CTCs were investigated using the CellSearch System
(Veridex, Raritan, NJ, USA). Peripheral blood was drawn into three
CellSave tubes (30 ml), sent at room temperature to the central
laboratory at the University of Munich, and examined within 
96 hours of collection.
The patient samples were then centrifuged for 10 minutes at
800 × g. The plasma was removed, and a dilution buffer was
added. This combination was overlaid on 6 ml of Histopaque
(Sigma, Steinheim, Germany) and centrifuged for 10 minutes at
400 × g. Subsequently, 7.5 ml of this sample enclosing the buffy
coat was treated on the CellTracks AutoPrep system using the
CellSearch Epithelial Cell Kit (Veridex). After immuno-magnetic
enrichment with an antibody to epithelial cell adhesion molecule
(EpCAM), the cells were marked with fluorescent anti-cytokeratin
(CK8,18,19–phycoerythrin) and anti-CD45 (CD45–allophycocyan)
antibodies, and 4,6-diamidino-2-phenyl-indole-dihydrochloride
was used to identify the intact cells.
Patients included. In this study, 200 patients of the SUCCESS study
were included and assigned into two groups: 100 Patients were
CTC-positive (group 1) and the other 100 patients were CTC-
negative (group 2). These two groups were then framed and
investigated accordingly. Patients from the respective groups were
then matched into pairs of two according to histopathological
grading, lymph node involvement, hormone receptor type, TNM
classification and survival vs. tumour associated death. Out of 200
patient samples that were investigated, 160 patients were still alive
at the last observation after the end of therapy and 40 patients had
died from their tumour during therapy. The groups investigated
included 98 patients with tumour graded G2 and 102 patients graded
G3. Matching criteria of the 200 patient collective did not allow
patients with grade G1. Tumour stage of the anamnestic diagnosis
was classified according to the TNM classification, which was
conducted accordingly to the WHO system (13). The matching of
patients was performed according to the criteria at the time of
primary diagnosis. The histopathological grading was classified
according to the Bloom and Richardson system classification (14). 
Detection of CTCs and cytokine determination. The identification
and enumeration of CTCs were achieved using CellTracks Analyzer
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II. CTCs were defined as nucleated cells lacking CD45 and
expressing cytokeratin. All positive samples were assessed by two
independent investigators. Samples with a minimum of one CTC
per 30 ml of blood were regarded as CTC-positive. 
The blood from 84 persons with no clinical evidence of
malignant disease was processed blinded and used as a negative
control. Four of these negative controls (4.9%) contained cells that
fit the definition of epithelial cells and which could be interpreted
as CTCs (one control had one, two controls had two, and one
control had three epithelial cells). For the measurement of cytokines
a commercial enzyme-linked immunosorbent assay (ELISA) was
used to screen the blood serum samples for the Th1 cytokines: IFN-
γ, TNF-α, IL-12, IL-1α, IL-1β, IL-2 and IL-18. The ELISA kits
used were acquired by Meso Scale Discovery® (Rockville, MD,
USA). We used anti-species multi-array 96-well plates for the
development of a sandwich immunoassay (see Figure 1). The 10
spot Multi Spot plates were pre-coated with capture antibodies on
independent and well defined spots that enabled us to immobilize a
primary capture antibody against the protein of interest - specific
for each cytokine (IFN-γ, TNF-α, IL-12, IL-1α, IL-1β, IL-2 and IL-
18). Standards and samples were also added to the appropriate
wells. A standard curve was run with each assay. We firstly added
the blood serum, calibrator and control then incubated plates at
room temperature with shaking for 2 h. After removing excess
sample from the well with wash buffer, we added the solution
containing the detection (anti-target) antibody conjugated with
electrochemiluminescent labels over the course of two incubation
periods. During incubation, where time slots differed in each test,
the target present in the sample bound to the capture antibody
immobilized on the working electrode surface by the anti-species
antibody. Recruitment of the labelled detection antibody by the
bound target completed the sandwich. After a second shaking and
incubation (time differed for each test), wash buffer was used to
remove the entire unbound enzymes and an MSD Read Buffer was
added to produce the appropriate chemical environment for
electrochemiluminescence. We then loaded the plate into an MSD
instrument (MESO QuickPlex SQ 120) for analysis where voltage
applied to the plate electrodes caused the captured labels to emit
light. The instrument measured the intensity of the emitted light to
present a quantitative measure of the amount of the protein of
interest that was present in the sample (15, 16) (see homepage:
www.mesoscale.com). 
Statistical analysis. Statistical analysis was accomplished using
SPSS 22.0 (IBM Corp., Armonk, NY, USA).
We evaluated the relationship between each cytokine of the Th1
group (IFN-γ, TNF-α, IL-1α, IL-1β, IL-2, IL-12 and IL-18) and
each matching criterion (CTC-positive vs. CTC-negative; survival
vs. death; grade 2 vs. grade 3; lymph node involvement vs. no
lymph node involvement; triple hormone receptor-positive vs. triple
hormone receptor-negative; progesterone receptor-positive vs.
progesterone receptor-negative; oestrogen receptor-positive vs.
oestrogen receptor-negative; HER2/neu receptor-positive vs.
HER2/neu receptor-negative) by using the non-parametric Spearman
correlation coefficient. Each parameter to be considered was
required to have a p-value of less than 0.05. Statistically significant
results for the Spearman correlation coefficient were then assessed
with the non-parametric Mann-Whitney-U rank-sum test. Moreover,
variables were examined by the use of box-plot analysis. All
statistical tests were considered significant at p<0.05. 
Results 
CTC-positive vs. CTC-negative patients. In the CTC-positive
patient group, patients with no lymph node involvement had
high levels of IL-1α, whereas those with lymph node
involvement expressed low levels of IL-1α (Spearman
correlation coefficient p=0.042, Mann–Whitney U-test
p=0.043; Figure 1a).
On the other hand, analysis of the CTC-negative collective
showed that patients with progesterone receptor-negative
disease had higher levels of IL-1β in comparison to those
with progesterone receptor-positive disease (Spearman
correlation coefficient p=0.028, Mann–Whitney U-test
p=0.029; Figure 1b).
However, statistical analysis found no significant
difference according to the presence or absence of CTCs in
patients with breast cancer in regard to the levels of IFN-γ,
TNF-α, IL-2 and IL-18.
Patient survival. The box plot analysis of the collective of
patients who remained alive revealed that patients with lymph
node involvement also had higher levels of IL-12p40.
(Spearman correlation coefficient p=0.041, Mann–Whitney U-
test p=0.041; Figure 2a). Statistically significant correlations
were also proven for patients with triple hormone receptor-
negative compared to -positive breast cancer, with the former
displaying significantly higher levels of IL-12p40. (Spearman
correlation coefficient p=0.042, Mann–Whitney U-test
p=0.043; see Figure 2b).
In comparison, in the group of patients who died,
patients with oestrogen receptor-negative tumour had
higher levels of IL-1α and IL-1β (Spearman correlation
coefficient p=0.049, Mann–Whitney U-test p=0.050 for
IL-1 α; Spearman correlation coefficient p=0.032, Mann–
Whitney U-test p=0.034 for IL-1β; Figure 3b and c
respectively). A significant correlation was also found for
patients with triple hormone receptor-negative breast
cancer having higher levels of IL-1α. (Spearman
correlation coefficient p=0.031, Mann–Whitney U-test
p=0.033; Figure 3a).
Statistical examination confirmed no significant difference
regarding the survival or death of patients with breast cancer
in regard to the levels of IFN-γ, TNF-α, IL-2, and IL-18.
Grading 2 vs. grade 3 tumour. In the collective with grade 2
tumour, patients with no lymph node involvement had higher
levels of IL-1 α (Spearman correlation coefficient p=0.013,
Mann–Whitney U-test p=0.014; Figure 4a). Patients with
grade 2 HER2/neu-positive breast cancer also had higher
levels of IFN-γ (Spearman correlation coefficient p=0.030,
Mann–Whitney U-test p=0.031; Figure 4b). 
In patients with grade 3 tumours, those with
progesterone receptor-negative disease had higher levels
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of IL-12p70 (Spearman correlation coefficient p=0.048;
Mann–Whitney U-test p=0.048; Figure 5a). Patients with
grade 3 tumours had a significantly higher IL-12p40
release in those with triple hormone receptor-positive
status compared to those with triple-negative disease
(Spearman correlation coefficient p=0.032; Mann–Whitney
U-test p=0.033; Figure 5b). None of the other cytokines
tested revealed differences in expression patterns in terms
of tumour grading. 
Lymph node involvement. Statistical analysis demonstrated no
significant difference concerning lymph node involvement or
no lymph node involvement in patients with breast cancer with
and without the presence of CTCs in respect to the cytokine
levels of IFN-γ, TNF-α, IL-12, IL-1α, IL-1β, IL-2 and IL-18. 
Hormone receptor type presence vs. absence. Furthermore,
the statistical analysis also verified no significant difference
regarding the presence or absence of single hormone receptor
ANTICANCER RESEARCH 36: 5227-5236 (2016)
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Figure 1. a: Left panel: Box plot analysis of interleukin 1-alpha (IL-1α) expression in sera of patients with circulating tumour cell (CTC)-positive
breast cancer. IL-1α release was significantly higher in patients without lymph node metastasis compared to patients with lymph node involvement
(p=0.043). Right panel: Receiver operator curve analysis of sensitivity versus specificity gave an area under the curve (AUC) of 0.402. b: Left
panel: Box plot analysis of interleukin 1 beta (IL-1β) expression and patients with CTC-negative disease. IL-1β release was significantly higher in
those with progesterone receptor-negative compared to those with progesterone receptor-positive breast cancer (p=0.029). Right panel: Receiver
operator curve analysis of sensitivity versus specificity gave an AUC of 0.372. Boxes indicate the 25th and 75th percentiles, with a horizontal line
at the median and bars display the 5th and 95th percentiles. Circles specify values more than 1.5 box lengths. Asterisks specify values (marked with
a number) more than 3.0 box lengths from the 75th percentile. 
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types (progesterone receptor, oestrogen receptor, HER2/neu)
in patients with breast cancer with and without the presence
of CTCs in regards to the levels of IFN-γ, TNF-α, IL-12, IL-
1α, IL-1β, IL-2 and IL-18. 
Triple positive vs. triple negative. No statistically
significant correlation was demonstrated with the general
comparison of triple-negative to triple-positive breast
cancer with and without the presence of CTCs in respect to
the cytokine levels of IFN-γ, TNF-α, IL-12, IL-1α, IL-1β,
IL-2 and IL-18. 
Discussion
In this study, we described Th1-derived cytokines in the sera
of patients with breast cancer with and without CTCs. The
group of patients diagnosed with CTCs and no lymph node
involvement had significantly enhanced IL-1α levels. IL-1α
is a Th1 cytokine derived from tumour cells. It is
hypothesized that cell senescence increases IL-1α
expression and creates a microenvironment that is
conducive to metastatic disease progression in patients with
cancer (17). Therefore IL-1α might be involved in
Vilsmaier et al: CTCs in Patients with Breast Cancer
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Figure 2. Box plot analysis of interleukin 12p40 (IL-12p40) expression in sera of patients who remained alive [regardless of circulating tumour cell
(CTC) status] according to lymph node involvement (a) and hormone receptor status (b). IL-12p40 release was significantly higher in patients who
remained alive and had lymph node metastasis compared to patients without lymph node involvement (p=0.041) (a, left panel), and in patients with
triple-positive hormone receptor status compared to those with triple-negative hormone receptor disease (p=0.043) (b, left panel). Receiver operator
curve analysis of sensitivity versus specificity gave an area under the curve of 0.599 (a, right panel) and 0.395 (b, right panel) respectively. Boxes
indicate the 25th and 75th percentiles, with a horizontal line at the median and bars display the 5th and 95th percentiles. Circles specify values
more than 1.5 box lengths. Asterisks specify values (marked with a number) more than 3.0 box lengths from the 75th percentile. 
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Figure 3. a: Box plot analysis of interleukin 1-alpha (IL-1α) expression in sera of patients who died from their disease [regardless of circulating
tumour cell (CTC) status] according to triple hormone receptor status (a) and oestrogen receptor status (b) and of IL-1β according to oestrogen
receptor status (c). Significantly higher IL-1α release was found in patients who died with triple-negative hormone receptor status compared to
patients with triple-positive hormone receptor (p=0.031) (a, left panel), and in those with oestrogen receptor-negative compared to those with
oestrogen receptor-positive cancer (p=0.049) (b, left panel). Similarly, we identified significantly increased IL-1β release in those with oestrogen
receptor-negative compared to those with oestrogen receptor-positive cancer (p=0.034) (c, left panel). Receiver operator curve analysis of sensitivity
versus specificity gave an area under the curve of 0.688, 0.350 and 0.286 (right panel, a, b and c, respectively). Boxes indicate the 25th and 75th
percentiles, with a horizontal line at the median and bars display the 5th and 95th percentiles. Circles specify values more than 1.5 box lengths.
Asterisks specify values (marked with a number) more than 3.0 box lengths from the 75th percentile. 
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circulation-specific metastasis and not metastasis via the
lymphatic system. This hypothesis is furthermore supported
by increased levels of IL-1α in patients with grade 2
tumours and no lymph node involvement. These findings
identify IL-1α as a crucial factor for the ability of senescent
cells to generate a tissue microenvironment that stimulates
cancer expansion (18). The abnormal increased expression
of IL-1α in less differentiated breast cancer cells with no
lymph metastasis might be responsible for local
invasiveness and malignant behaviour.
Significantly enhanced IL-1α levels were also found in
patients with triple hormone receptor-negative breast cancer
who died from their disease. Furthermore, increased IL-1α
and IL-1β levels were shown for patients who died from
oestrogen receptor-negative breast cancer. It is conjectured
that IL-1α expressed on malignant cells stimulates
antitumour immunity, while IL-1β that originates from the
microenvironment or malignant breast cancer cells activates
inflammation that increases invasiveness and induces tumour
suppression (12, 19, 20). Therefore, one can suggest that
Vilsmaier et al: CTCs in Patients with Breast Cancer
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Figure 4. Box plot analysis of interleukin 1-alpha (IL-1α) (a) and interferon gamma (IFN-γ) (b) expression in sera of patients with grade 2 (G2)
tumour [regardless of circulating tumour cell (CTC) status]. IL-1α release was significantly higher in the G2 patient collective with no lymph node
metastasis compared to patients with lymph node involvement (p=0.013) (a, left panel). Significantly enhanced IFN-γ release was shown in the G2
patient collective with HER2/neu receptor-positive compared to HER2/neu receptor-negative breast cancer (p=0.030) (b, left panel). Boxes indicate
the 25th and 75th percentiles, with a horizontal line at the median and bars display the 5th and 95th percentiles. Circles specify values more than
1.5 box lengths. Asterisks specify values (marked with a number) more than 3.0 box lengths from the 75th percentile. Receiver operator curve
analysis of sensitivity versus specificity gave an area under the curve of 0.322 (a, right panel) and 0.676 (b, right panel), respectively. 
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increased expression of IL-1α and IL-1β in patients with a
triple-negative hormone status who died, especially in terms
of negative oestrogen receptor status, is potentially
responsible for the severity of tumour malignancy and local
invasiveness, ultimately resulting in the death of those
patients. We can consequently also infer that the
manipulation of IL-1α and IL-1β in malignant cells or in the
tumour microenvironment could offer new approaches in
terms of cancer therapy for patients with triple-negative
breast cancer. Furthermore, significantly enhanced IL-1β
expression in patients diagnosed as having progesterone
receptor-negative breast cancer not having CTCs might
indicate the involvement of IL-1β in local invasiveness
rather than circulation, leading to less favourable outcome.
Regardless of CTC status, in patients who survived, we
identified significantly enhanced IL-12p40 release in
combination with a triple-positive hormone receptor status
and lymph node metastasis. It is hypothesized that IL-12 has
an anti-angiogenetic effect and the ability to induce a T-cell-
based antitumour immune response capable of eliminating
ANTICANCER RESEARCH 36: 5227-5236 (2016)
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Figure 5. a: Box plot analysis of interleukin 12p70 (IL-12p70) (a) and IL-12p40 expression in sera of patients with grade 3 (G3) tumour (regardless
of circulating tumour cell (CTC) status). IL-12p70 release was significantly higher in patients with progesterone receptor-negative compared to
those with progesterone receptor-positive breast cancer (p=0.048) (a, left panel). IL-12p40 release was significantly higher in those with triple-
positive compared to patients with triple-negative breast cancer (p=0.032) (b, left panel). Boxes indicate the 25th and 75th percentiles, with a
horizontal line at the median and bars display the 5th and 95th percentiles. Circles specify values more than 1.5 box lengths. Asterisks specify
values (marked with a number) more than 3.0 box lengths from the 75th percentile. Receiver operator curve analysis of sensitivity versus specificity
gave an area under the curve of 0.384 (a, right panel) and 0.377 (b, right panel), respectively. 
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disseminated cancer cells (21, 22). It has already been
implied that intratumoural treatment of patients with breast
cancer with IL-12 in combination with other cytokines leads
to infiltration by polymorphonuclear cells, dendritic cell
antigen presentation and CD8+ T-cells, with consequent
tumour regression. Furthermore, it has been shown that local
IL-12 therapy stimulates specific antitumor T-cells in lymph
nodes resulting in a memory immune response (23),  and is
even capable of eradicating disseminated tumour cells (20,
24). An enhanced IL-12p40 level in this collective of
survivors with triple-positive hormone receptor status
therefore indicates a natural advantage, most probably
responsible for local apoptosis, eradicating distant disease
and thus enhancing survival. However, in our study, patients
with lymph node metastasis, indicating a highly malignant
phenotype, nevertheless survived. The increased IL-12p40
expression in these patients emphasises antitumour immune
response in distant metastatic lesions in lymph nodes,
increasing a favourable outcome. Moreover, we identified
significantly enhanced IL-12p40 release in the patient
collective with grade 3 triple-positive breast cancer. A pattern
of increased IL-12p40 expression together with a significant
increase in the total number of lymphocytes, CD4+, CD8+,
natural killer cells and C-reactive protein has been described
to be of clinical benefit, as opposed to progression, in
hormone-responsive metastatic breast cancer (25). One can
suppose an association exists between triple-positive breast
cancer and enhanced IL-12p40 expression, furthermore
responsible for counteracting the malignant invasiveness of
a poorly differentiated tumour. Moreover, the significantly
enhanced IL-12p70 release in patients with grade 3
progesterone receptor-negative disease suggests a direct
association between IL-12p70 and the absence of
progesterone receptor in poorly differentiated tumours.
Patients with grade 2 HER2/neu receptor-positive breast
cancer, regardless of CTC status, had a significantly higher
IFN-γ expression. IFN-γ is purportedly responsible for
promoting apoptosis by enhancing cytotoxic T-lymphocyte
activity and influencing p53 expression, associated with a
protective role against cancer (11, 26). It is furthermore
presumed that IFN-γ genetic polymorphisms might even be
significantly related to a higher risk of breast cancer (27).
Therefore, significantly enhanced IFN-γ expression in
patients with less differentiated (grade 2) and HER2/neu
receptor-positive breast cancer may enhance tumour
apoptosis, resulting in a more favourable outcome.
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Abstract:	  	  
Background/Aim:	  Circulating	  tumor	  cells	  (CTCs)	  in	  women	  with	  breast	  cancer	  are	  an	  indication	  of	  prognosis	  before	  starting	  systemic	  treatment.	  The	  aim	  of	  this	  study	  was	  the	  evaluation	  of	  cytokine	  profiles	  as	  marker	  for	  CTC	  involvement.	  
Materials	   and	   Methods:	   The	   analysis	   of	   CTCs,	   the	   time	   of	   blood	   sampling	   and	   the	  methodology	   were	   prospectively	   designed.	   There	   were	   two	   groups	   of	   patients:	   100	  women	  with	  a	  positive	  result	   for	  presence	  of	  CTCs	  and	  100	  women	  negative	   for	  CTCs.	  These	   groups	  were	  matched	   into	   pairs	   by	   tumor	   factors	   and	   survival/death.	   A	  multi-­‐array	   ELISA	   was	   used	   to	   screen	   T-­‐helper	   cell	   (Th)	   2	   cytokines.	   The	   results	   were	  analyzed	  by	  Spearman	  correlation	  coefficient	  and	  Mann-­‐Whitney	  U-­‐test.	  
Results:	   In	  patients	  who	  were	  CTC-­‐negative,	  expression	  of	  interleukin-­‐8	  (IL-­‐8)	  and	  IL-­‐13	   was	   increased	   (p=0.017	   and	   p=0.045,	   respectively)	   if	   they	   were	   negative	   for	  progesterone	   receptor.	   In	   patients	   who	   died	   from	   their	   tumor,	   correlation	   between	  hormone	  receptor	  negativity	  and	  an	   increase	   in	   IL-­‐4	  was	   found.	   IL-­‐5	  was	   increased	   in	  patients	   with	   lymph	   node-­‐positive	   and	   human	   epidermal	   growth	   factor	   receptor	   2	  (HER2)-­‐positive	   disease	   (p=0.042).	   Moreover,	   IL-­‐4	   was	   increased	   in	   patients	   with	  progesterone	   receptor-­‐positive	   and	   estrogen	   receptor-­‐negative	   status	   (p=0.024).	  Furthermore,	   the	   level	  of	   IL-­‐6	  was	   increased	   in	  patients	  with	   tumor	  grade	  G3	  without	  progesterone	  receptor	  expression.	  
Conclusion:	  Th2	  cytokines	  are	  significantly	  modified	  in	  patients	  who	  are	  CTC-­‐negative	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and	   progesterone	   receptor-­‐positive.	  We	   suppose	   that	   an	   increase	   of	   IL-­‐4	   depends	   on	  hormone	   receptor	   status.	   In	   literature,	   a	   correlation	   between	   IL-­‐4	   and	   resistance	   to	  apoptosis	  is	  described.	  We	  suspect	  that	  IL-­‐4	  is	  responsible	  for	  the	  poor	  outcome	  of	  these	  cases.	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Abstract. Background/Aim: Circulating tumor cells (CTCs)
in women with breast cancer are an indication of prognosis
before starting systemic treatment. The aim of this study was
the evaluation of cytokine profiles as marker for CTC
involvement. Materials and Methods: The analysis of CTCs,
the time of blood sampling and the methodology were
prospectively designed. There were two groups of patients:
100 women with a positive result for presence of CTCs and
100 women negative for CTCs. These groups were matched
into pairs by tumor factors and survival/death. A multi-array
ELISA was used to screen T-helper cell (Th) 2 cytokines. The
results were analyzed by Spearman correlation coefficient
and Mann–Whitney U-test. Results: In patients who were
CTC-negative, expression of interleukin-8 (IL-8) and IL-13
was increased (p=0.017 and p=0.045, respectively) if they
were negative for progesterone receptor. In patients who died
from their tumor, correlation between hormone receptor
negativity and an increase in IL-4 was found. IL-5 was
increased in patients with lymph node-positive and human
epidermal growth factor receptor 2 (HER2)-positive disease
(p=0.042). Moreover IL-4 was increased in patients with
progesterone receptor-positive and estrogen receptor-
negative status (p=0.024). Furthermore, the level of IL-6 was
increased in patients with tumor grade G3 without
progesterone receptor expression. Conclusion: Th2 cytokines
are significantly modified in patients who are CTC-negative
and progesterone receptor-positive. We suppose that an
increase of IL-4 depends on hormone receptor status. In
literature, a correlation between IL-4 and resistance to
apoptosis is described. We suspect that IL-4 is responsible
for the poor outcome of these cases. 
The detection of circulating tumor cells (CTCs) is an
independent prognostic factor for progression-free and overall
survival for patients with metastatic and newly diagnosed
breast cancer (1). The presence of CTCs is associated with
poor disease-free survival (DFS), distant DFS, breast cancer-
specific survival, and overall survival (2). The repeated
detection of CTCs can help to evaluate the success of treatment
in patients with breast cancer (3). The role of CTCs in patients
with breast cancer is being analyzed in the SUCCESS study.
This is a trial to differentiate the prognostic significance
associated with reduced survival of patients with CTCs in early
breast cancer before starting systemic adjuvant treatment and
after adjuvant treatment in a large patient cohort (2). The
intention of our study was the evaluation of cytokine profiles as
an indicator for CTC involvement in patients with breast
cancer. The involvement of the lymphatic system, especially
lymphocytes, can play a major role in the progression of breast
cancer (4). T-Lymphocytes and their cytokines interact with
tumor cells and can influence on the prognosis (5). Through
their tumor-promoting or tumor-suppressive properties,
cytokines can influence the progression of cancer. Some
cytokines of the Th2 subgroup [interleukin (IL-)6, and IL-10]
found at higher levels in patients with cancer are associated
with worse prognosis in terms of overall and DFS (6).
Therefore we wanted to analyze such cytokines, especially to
determine their levels in patients with breast cancer.
We used the serum of patients with breast cancer who took
part in the SUCCESS study. Data on CTC involvement,
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histopathological grading, lymph-node status, hormone-
receptor type, TNM classification and survival of patients with
breast cancer vs. those who died of their disease were collected. 
The aim of this study was the investigation of a panel of
Th2 cytokines in a group of patients with breast cancer
diagnosed with CTCs (n=100) and in a control group
negative for CTCs (n=100). 
Materials and Methods
Study design. All patients who participated were women with breast
cancer (stages pT1-T4, pN0 – N3, M0) who took part in the phase I
SUCCESS study. In the SUCCESS study, which was a prospective,
randomized adjuvant study in which the following therapy regimes
were compared: three cycles of fluorouracil– epirubicin–
cyclophosphamide (FEC; 500/100/500 mg/m2) followed by three
cycles of docetaxel (100 mg/m2) every 3 weeks vs. three cycles of
FEC followed by three cycles of gemcitabine (1,000 mg/m2 days 1
and 8) with docetaxel (75 mg/m2) every 3 weeks. After completing
chemotherapy, patients were randomized to receive either 2 years or
5 years of therapy with the bisphosphonate zoledronate. Women with
hormone receptor-positive tumors received endocrine therapy. The
questions of research corresponding on CTC analysis, blood
sampling time points and the methodology, were prospectively
created. As a scientific objective of the study protocol, the
prognostic value of CTCs was characterized. The SUCCESS study
was managed in agreement with the Declaration of Helsinki and it
was permitted by 37 German ethical boards (the leading ethical
board was the LMU, Munich). Blood sampling for CTC
enumeration was carried out for 2,090 patients after the primary
tumor was completely removed by surgery and before starting
adjuvant chemotherapy. In 64 cases, study participation was not
possible because of test failures or the time interval between blood
collection and sample preparation was too long (>96 h). There was
a follow-up analysis for a subgroup of 1,492 patients after
chemotherapy and before the start of endocrine or bisphosphonate
therapy (see homepage: http://www.success-studie.de).
Patients. A total of 200 patients of the SUCCESS study were
included in our study and they were divided into two groups: One
collective with 100 patients who were CTC-positive and the second
group with 100 patients who were CTC-negative. These groups
were matched into pairs by histopathological grading, lymph-node
status, hormone-receptor type, TNM classification and survival
versus tumor-related death. Of all these 200 patients, 160 were still
alive at the last monitoring after the end of therapy and 40 patients
had died during therapy due to their tumor. The collective included
98 patients with a tumor of grade G2 and 102 patients with a tumor
of grade G3. Patients with a tumor of grade G1 were not included.
The stage of the tumor was classified according to the TNM
classification (WHO System) (7). Patients were matched in
agreement with the criteria. Histopathological grading of the tumors
was categorized according to the Bloom and Richardsen system (8).
Collection of blood samples and detection of CTCs. The method
was carried out as described by the SUCCESS Study group (2)
using the CellSearch System (Janssen Diagnostics, South Raritan,
NJ, USA). After peripheral blood was drawn into three CellSave
tubes (30 ml), the examination was arranged at the central
laboratory at the University of Munich. It was necessary to examine
the blood samples within 96 hours of collection. In brief,
identification and enumeration of CTCs were achieved using a
CellTracks Analyzer II (Janssen Diagnostics). CTCs were defined
as nucleated cells lacking CD45 and expressing cytokeratin. In the
case of positive samples, two independent investigators made the
evaluation. All samples with a minimum of one CTC per 30 ml of
blood were indexed as being CTC-positive. Blood samples from 84
individuals without clinical evidence of malignant disease were
processed blind and used as a negative control. In four cases of
these negative controls (4.9%), there were cells that fit the definition
of epithelial cells and which could be interpreted as CTCs (one
control with one epithelial cell, two controls with two, and one
control with three epithelial cells).
Measurement of cytokines. For screening the blood serum samples
for the Th2 cytokines IL-4, IL-5, IL-6, IL-8 and IL-13, a recently
developed multicytokine/chemokine ELISA array (Meso Scale
Discovery®, Rockville, MD, USA) was used to screen for the Th2
cytokines: IL-4, IL-5, IL-6, IL-8 and IL-13. In our case, anti-
species MULTI-ARRAY 96-well plates for the development of a
sandwich immunoassay were used. The 10 spot MULTI-SPOT
plates were useful to immobilize a primary capture antibody
against the specific protein of interest specific for each cytokine
(IL-4, IL-5, IL-6, IL-8 and IL-13). We added standards and samples
to the appropriate wells. Firstly we added the blood serum,
calibrator and control then incubated plates at room temperature
with shaking for 2 hours. We then removed the excess sample from
each well with wash buffer, and added antibody conjugated with
electrochemiluminescent labels over the course of two incubation
periods. After a second incubation with shaking (time was different
for each test), wash buffer was used to remove the entire unbound
enzymes and MSD Read Buffer was added to produce the
appropriate chemical environment for electrochemiluminescence.
The plate was then loaded into an MSD instrument (MESO
QuickPlex SQ 120) to measure the intensity of the emitted light as
a quantitative measure of the amount of the protein of interest that
was present in the sample (9, 10) (see www.mesoscale.com) by
comparison with a standard curve for each assay. 
Statistical analysis. For statistical analysis, SPSS 22.0 (SPSS Inc.,
IBM, Chicago, IL- USA) was used. The relationship between each
cytokine of the Th2 group (IL-4, IL-5, IL-6, IL-8 and IL-13) and
each factor studied was determined using the non-parametric
Spearman correlation coefficient (p-values reported). All the
statistically significant results by Spearman correlation coefficient
were furthermore confirmed with the non-parametric Mann–Whitney
U-rank sum test. Variables were examined by using box-plot
analysis. All statistical tests were considered significant at p<0.05.
Results
CTC-positive vs. CTC-negative status. CTC-negative patients
who were progesterone receptor-negative had a higher level
of IL-8 in contrast to patients positive for progesterone
receptor (Spearman correlation p-value=0.017, Mann–Whitney
U-test p=0.017; Figure 1a).
The same effect was shown for higher levels of IL-13 in
patients who were CTC-negative: In the group without
ANTICANCER RESEARCH 36: 3123-3130 (2016)
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expression of progesterone receptor, IL-13 was increased
(Spearman correlation p=0045, Mann–Whitney U-test
p=0.045; Figure 1b).
Regarding the patient group with breast cancer with the
presence of CTCs, there was no significant difference in the
statistical analysis relating to levels of Th2 cytokines (IL-4,
IL-5, IL-6, IL-8 and IL-13).
Survival vs. death. In the group of patients who died, the box-
plot analysis revealed that patients with progesterone receptor-
negative status had a higher level of IL-4 than patients with
progesterone receptor-positive status (Spearman correlation
p=0.015, Mann–Whitney U-test p=0.017; Figure 2a).
The same pattern was found in patients negative for estrogen
receptor expression: box-plot analysis indicated a higher level
Ko¨nig et al: Th2 Cytokines in BC Patients
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Figure 1. Box-plot analysis of interleukin (IL)-8 (a) and IL-13 (b) expression in serum of patients with breast cancer negative for circulating tumor
cells (CTCs) according to progesterone receptor status. The range between the 25th and 75th percentiles is represented by boxes with a horizontal
line at the median. The bars show the 5th and 95th percentiles. Circles indicate values more than 1.5 box lengths. Asterisks indicate values (marked
with a number) more than 3.0 box lengths from the 75th percentile. We identified significantly enhanced expression of IL-8 in patients with no CTCs
and progesterone receptor-negative breast cancer compared to those who had progesterone receptor-positive disease (p=0.017) (a, left panel).
Receiver operator curve analysis of sensitivity versus specificity of the ELISAs used was performed and gave area under the curve values of 0.361
(a, right panel) and 0.383 (b, right panel), respectively. 
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of IL-4 in comparison with patients positive for estrogen
receptor (Spearman correlation p=0.045, Mann–Whitney U-
test p=0.046; Figure 2b).
Regarding the patient group with breast cancer who were
still alive, there was no significant difference in statistical
analysis relating to Th2-cytokine levels (IL-4, IL-5, IL-6, IL-
8 and IL-13).
Grade G2 vs. G3 tumor. The collective with grade G3 tumor
was associated with statistically significant results based on
ANTICANCER RESEARCH 36: 3123-3130 (2016)
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Figure 2. Box-plot analysis of interleukin (IL)-4 expression in serum of patients with breast cancer who died from their disease (regardless of
circulating tumor cell status) according to progesterone (a) and estrogen (b) receptor status. The range between the 25th and 75th percentiles is
represented by boxes with a horizontal line at the median. The bars show the 5th and 95th percentiles. Circles indicate values more than 1.5 box
lengths. Asterisks indicate values (marked with a number) more than 3.0 box lengths from the 75th percentile. We identified significantly enhanced
expression of IL-4 in the collective who died with progesterone receptor-negative breast cancer compared to those with progesterone receptor-
positive disease (p=0.017) (a, left panel), and in those who died with estrogen receptor-negative disease compared with those with estrogen receptor-
positive disease (p=0.046) (b, left panel). Receiver operator curve analysis of sensitivity versus specificity of the ELISA used was performed and gave
area under the curve values of 0.276 (a, right panel) and 0.299 (b, right panel), respectively.
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Figure 3. Box plot analysis of interleukin (IL)-6, IL-8 and IL-13 (left panels of a, b and c, respectively) in sera of patients with G3 breast cancer
(regardless of circulating tumor cell status). The range between the 25th and 75th percentiles is represented by boxes with a horizontal line at the
median. The bars show the 5th and 95th percentiles. Circles indicate values more than 1.5 box lengths. Asterisks indicate values (marked with a
number) more than 3.0 box lengths from the 75th percentile. In addition, receiver operator curve (ROC) analysis of sensitivity versus specificity of
the ELISAs used was performed and the area under the curve (AUC) value was derived (a-c, right panels). We identified significantly enhanced IL-
6 release in the G3 patient collective with progesterone receptor-negative breast cancer compared to patients with progesterone receptor-positive
disease (p=0.027) (a, left panel), with an AUC in ROC analysis of 0.370 (a, right panel). Similarly, IL-8 (b) and IL-13 (c) release were also
significantly greater in patients with G3 progesterone receptor-negative breast cancer compared to their counterparts with progesterone receptor-
positive disease (p=0.033 and p=0.019, respectively), with AUCs of 0.375 and 0.361, respectively (b and c, right panels). 
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hormone receptor status and cytokine levels: in progesterone
receptor-negative cases, levels of IL-6, IL-8 and IL-13 were
increased in comparison to patients with progesterone
receptor-positive cases (IL-6: Spearman correlation
p=0.026, Mann–Whitney U-test p=0.027; IL-8: Spearman
correlation p=0.032, Mann–Whitney U-test p=0.033; IL-13:
Spearman correlation p=0.018, Mann–Whitney U-test
p=0.019; Figure 3).
Regarding the patient group with G2 grade tumor, there
was no significant difference in the statistical analysis
relating to Th2-cytokine levels (IL-4, IL-5, IL-6, IL-8 and
IL-13).
ANTICANCER RESEARCH 36: 3123-3130 (2016)
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Figure 4. Box plot analysis of interleukin (IL)-5 expression in sera of patients with breast cancer with lymph node metastasis (regardless of
circulating tumor cell status). The range between the 25th and 75th percentiles is represented by boxes with a horizontal line at the median. The bars
show the 5th and 95th percentiles. Circles indicate values more than 1.5 box lengths. Asterisks indicate values (marked with a number) more than
3.0 box lengths from the 75th percentile. We identified significantly enhanced IL-5 release in patients with lymph node metastasis and HER2/NEU-
positive breast cancer compared to their counterparts with HER2/NEU-negative breast cancer (p=0.043) (left panel). Receiver operator curve
analysis of sensitivity versus specificity of the ELISA used gave an area under the curve of 0.626 (right panel).
Figure 5. Box plot analysis of interleukin (IL)-4 expression in sera of patients with progesterone receptor-positive breast cancer (regardless of
circulating tumor cell status). The range between the 25th and 75th percentiles is represented by boxes with a horizontal line at the median. The bars
show the 5th and 95th percentiles. Circles indicate values more than 1.5 box lengths. Asterisks indicate values (marked with a number) more than
3.0 box lengths from the 75th percentile. We identified significantly enhanced IL-4 release in patients with progesterone receptor-positive, estrogen
receptor-negative breast cancer compared to their counterparts with estrogen receptor-positive disease (p=0.025) (left panel). Receiver operator
curve analysis of sensitivity versus specificity of the ELISA used gave an area under the curve of 0.277 (right panel).
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Lymph node involvement vs. no lymph node involvement. For
the collective with disease-positive lymph nodes, the box-plot
analysis disclosed that those who were HER2/neu receptor-
positive disease had higher levels of IL-5 in comparison to those
who were HER2/neu receptor-negative (Spearman correlation
p=0.042, Mann–Whitney U-test p=0.043; Figure 4a).
Regarding the group of patients without lymph node
involvement, no significant difference in the statistical
analysis relating to Th2 cytokine levels (IL-4, IL-5, IL-6, IL-
8 and IL-13) was found.
Hormone receptor status. Patients who were progesterone
receptor-positive and estrogen receptor-negative had high
levels of IL-4 (Spearman correlation p=0.024, Mann–Whitney
U-test p=0.025; Figure 5a).
However, in patients with both hormone receptor-negative
and HER2/neu-negative tumor, no significant difference in
statistical analysis relating to Th2 cytokine levels (IL-4, IL-
5, IL-6, IL-8 and IL-13) was detected.
Discussion
The background of this study was an investigation using the
serum of patients who participated in the SUCCESS I study.
The levels of cytokines of the Th2 group were monitored
depending on specific breast cancer criteria such as hormone
receptor status, lymph node involvement, grading, CTC
involvement and other criteria. In a specific number of
patients, statistically significant variations of the cytokine
levels were found.
Regarding IL-4, we found that its level increased in patients
who died and for whom the progesterone receptor or the
estrogen receptor was negative. The same effect was shown in
the patient group with at least one positive hormone receptor:
we found that the level of IL-4 was high when estrogen
receptor expression was negative. In all these cases, if the
tumor criteria showed a high level of IL-4, a poor prognosis
was described for breast cancer (11). In literature, IL-4 is
described in several reports to be involved in the pathogenesis
of cancer or development of local metastasis, especially in the
case of colorectal cancer (12, 13). Another finding was the
involvement of increasing IL-4 in increasing tumor cell
resistance to apoptosis (14). Regarding the results in our study,
with a higher level of IL-4 in patients we expected a poor
prognosis (hormone receptor-negative); we suspect that an
increase of IL-4 is responsible for the poor outcome in these
cases amongst others. A poorer outcome could be interpreted
as a higher risk of metastasis and the involvement of
resistance to apoptosis. Furthermore, the correlation of IL-4
and a negative outcome is supported by increased IL-4 levels
in our collective of patients who ultimately died.
Patients in our collective with lymph node involvement
and with expression of HER2/neu receptor had a significantly
higher level of IL-5 than patients with HER2/neu-negative
status. Breast cancer with lymph node involvement and with
expression of the HER2/neu receptor has a poor prognosis
(11). In the literature, we found only little information on the
role of IL-5 concerning cancer. On the other hand, in bladder
cancer, it was shown that an increased level of IL-5 enhanced
the migration and invasion of bladder cancer cells via
extracellular-signal-regulated kinase 1/2-mediated matrix
metallopeptidase 9/nuclear factor κ-light-chain-enhancer of
activated B-cells/activator protein 1 pathway (15).
In our collective, higher IL-5 was associated with poor
prognosis, hence we suspect that IL-5 modifies the invasion
of cancer or the development of metastasis in a negative
manner. 
Another investigated cytokine was IL-6, which was found
at a higher level in patients with a tumor grade of G3 and who
were negative for progesterone receptor. In literature, the pro
inflammatory cytokine IL-6 is to be held responsible for tumor
growth and differentiation in prostate cancer. IL-6 is also
described as having a proliferative and anti-apoptotic effect
(16). Furthermore, the serum IL-6 level is a potential biomarker
for predicting disease progression in colorectal cancer (17). In
our study, IL-6 was increased in patients with a poor prognosis
because of their tumor grading and receptor status. As seen in
the literature, IL-6 is associated with anti-apoptotic effect
which is likely responsible for poorer outcome in our cases.
The level of IL-8 was statistically significantly increased in
patients who were CTC-negative and without expression of
progesterone receptor. In cases with a tumor grade G3 and
negative for progesterone receptor, we also found an increased
IL-8 level. A correlation is implied between IL-8 and neo-
vascularization, which would encourage metastatic spread (18,
19). Hence increasing IL-8 is most likely responsible for the
increased risk of metastatic spread in these cases. Therefore,
IL-8 in patients CTC-negative and negative for progesterone
receptor might be involved in local invasiveness through
neovascularization. Furthermore an increase of IL-8 in our
patient collective with G3 progesterone receptor-negative
tumor supports a less favorable outcome. 
Levels of IL-13 were increased in CTC-negative patients
who were progesterone receptor-negative. The other
collective with a high level of IL-13 was characterized by
G3 tumor and no expression of progesterone receptor. Due
to the fact that IL-13 is increased in hormone receptor-
negative patients with G3 tumor, we expect that high
expression of IL-13 to be associated with a poorer prognosis
(11). In literature IL-13 is described to be involved in
negatively modulating the development of effective Th1
immunity (20). In human pancreatic cancer, IL-13 exerts
autocrine growth-promoting effects and its expression
correlates with a propensity for lymph node metastases (21).
Therefore, we may conclude that an increased IL-13 level is
related to hormone receptor negativity and poorly graded
Ko¨nig et al: Th2 Cytokines in BC Patients
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tumors but on the other hand also responsible for lymph
node metastasis and immunosuppression.
In summary, increased levels of Th2 cytokines seem to be
associated with a poor prognosis in breast cancer.
Measurement and interpretation of Th2 cytokines in breast
cancer could help develop new prognostic parameters or
therapeutic strategies.
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3.	  SUMMARY	  	  
	  Within	  this	  thesis	  we	  thoroughly	  describe	  the	  significant	  results	  of	  TH1	  and	  TH2	  derived	  cytokines	   of	   the	   T-­‐lymphocyte	   immune	   response	   including	   angiogenesis	  markers	   and	  disclose	  the	  differences	  of	  cytokine	  levels	  in	  breast	  cancer	  patients	  of	  the	  SUCCESS	  study	  group	  with	   respect	   to	   CTC	   involvement	   in	   hindsight	   to	   specific	   breast	   cancer	   criteria.	  Firstly,	  sFlt1	  values	  being	  significantly	  enhanced	  in	  those	  patients	  who	  survived,	  with	  no	  lymph	  node	  involvement,	  G2	  graded	  tumour, and	  altogether	  negative	  for	  CTCs	  suggests	  the	   anti-­‐vascular	   cytokine	   inhibits	   CTCs	   being	   released	   into	   the	   peripheral	   blood	  signifying	   an	   additive	   inhibition	   delay	   in	   tumour	   growth,	   triggering	   a	   significant	  disruption	  of	  tumour	  vascularization	  (63),	  consequently	  enhancing	  survival	  (18,	  64-­‐66).	  To	   continue,	   significantly	   enhanced	   PlGF	   values	   were	   revealed	   for	   the	   CTC	   negative	  patient	   collective	   and	   in	   the	   sera	   of	   survived	   patients	   with	   no	   CTC	   involvement,	  supporting	   the	   implication	   that	   tumour	   derived	   PlGF	   negatively	   modulates	   tumour	  angiogenesis	  and	  tumour	  progress	  (66).	  A	  functional	   interaction	  of	  sFlt1	  and	  PlGF	  was	  found,	   suggesting	   that	   their	   combined	   overexpression	   in	   tumour	   cells	   inhibits	   CTCs	  entering	   the	   peripheral	   blood.	   Furthermore,	   highlighting	   only	   the	   most	   significant	  results	  amongst	  the	  TH1	  derived	  cytokine,	  significant	  enhanced	  IL-­‐1α	  secretion	  in	  CTC	  positive	   patients	   were	   revealed.	   Increased	   values	   of	   this	   cytokine	  were	   also	   found	   in	  sera	   of	   patients	  without	   lymph	  node	   involvement.	   Thus,	   implying	   that	   IL-­‐1α	   can	   be	   a	  marker	   for	   the	   release	   of	   tumour	   cells	   into	   the	   circulation	   but	   not	   in	   the	   lymphatic	  system	   (42,	   67).	   Il-­‐1β	   on	   the	   other	   hand	   emphasised	   that	   only	   CTC	   negative	   patients	  showed	  a	  correlation	  of	  the	  progesterone	  receptor	  expression	  and	  Il-­‐1β	  release	  (39,	  43,	  44).	  Concluding,	  IL-­‐1α	  and	  IL-­‐1β	  are	  associated	  to	  CTC	  release	  in	  breast	  cancer	  patients.	  Similarly,	   the	  TH2	  cytokines	  exposed	  significantly	  modified	  values	   in	  patients	  who	  are	  CTC	  negative	  and	  showed	  progesterone	  receptor	  expression,	  suggesting	  that	  an	  increase	  of	   IL-­‐4	   is	   reliant	   on	   hormone	   receptor	   status.	   	   The	   correlation	   between	   IL-­‐4	   and	  resistance	  to	  apoptosis	  can	  be	  endorsed	  and	  be	  held	  responsible	  for	  the	  poor	  outcome	  of	  these	  cases	  (51-­‐53,	  68).	  In	  total,	  increased	  levels	  of	  TH2	  cytokines	  appear	  to	  be	  related	  with	  an	  unfortunate	  prognosis	  in	  breast	  cancer.	  The	  cytokine	  profiles	  revealed	  help	  for	  a	  profounder	   understanding	   of	   the	   illness	   and	   how	   immunological-­‐related	   genes	   affect	  breast	   carcinogenesis.	   Measurement	   and	   interpretation	   of	   cytokine	   profiles	   in	   breast	  cancer	   could	  help	  assess	   the	  discrete	   risk	  of	  patients	  at	   the	   time	  of	  primary	  diagnosis	  and	  even	  improve	  therapy	  observation	  and	  strategy.	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  Diese	  Dissertation	  beschreibt	  signifikante	  Unterschiede	  des	  Vorkommens	  von	  TH1,	  TH2	  und	   Angiogenese	   abgeleiteten	   Zytokinen	   bei	   Brustkrebspatientinnen	   der	   SUCCESS	  Studie	   in	  Hinblick	  auf	  CTC	  Beteiligung	   in	  Relation	  zu	  spezifischen	  Brustkrebskriterien.	  Der	   sFlt1	   Marker	   zeigt	   erhöhte	   Werte	   in	   der	   Gruppe	   der	   überlebenden	  Brustkrebspatientinnen	  sowie	  bei	  Patientinnen	  ohne	  Lymphknotenbeteiligung	  oder	  mit	  G2	  Tumoren.	  All	  die	  Gruppen	  waren	  allesamt	  negativ	  für	  CTCs.	  Dies	  impliziert	  das	  sFlt1,	  als	   antivaskulärer	   Trigger,	   eine	   Tumor-­‐Vaskularisation	   verhindert	   (63),	   das	  Tumorwachstum	   hemmt	   und	   folglich	   das	   Überleben	   verbessert	   (18,	   64-­‐66).	   Erhöhte	  PIGF	   Werte	   sind	   bei	   CTC-­‐negativen	   und	   überlebenden	   Patientinnen	   ohne	   CTC-­‐Beteiligung	  nachgewiesen.	  Schlussfolgernd	  befürwortet	  dies	  die	  These,	  dass	  vom	  Tumor	  sezerniertes	   PIGF	   die	   Angiogenese	   sowie	   die	   Tumor-­‐Progression	   negativ	   beeinflusst	  (66).	  Die	  nachgewiesene	  Wechselwirkung	  zwischen	  sFlt1	  und	  PIGF	  lässt	  vermuten,	  dass	  deren	   Überexpression	   in	   Tumorzellen	   die	   Freisetzung	   von	   CTCs	   in	   das	   periphere	  Blutsystem	  abwendet.	  Eines	  der	  hoch	  signifikanten	  Ergebnisse	   in	  der	  Gruppe	  der	  TH1	  abgeleiteten	  Zytokine	  ist	  die	  gesteigerte	  IL-­‐1α	  -­‐Sekretion	  bei	  CTC-­‐positiven	  Patientinnen	  sowie	  bei	  Patientinnen	  ohne	  Lymphknotenbeteiligung.	  Dies	  deutet	  darauf	  hin,	  dass	  die	  Präsenz	  von	  IL-­‐1α	  für	  die	  Freisetzung	  von	  Tumorzellen	  in	  den	  Kreislauf	  verantwortlich	  sein	  könnte,	  ein	  Progress	   in	  das	   lymphatische	  System	   jedoch	  verhindert	  (42,	  67).	  Eine	  erhöhte	   Il-­‐1β Konzentration	   kann	   bei	   CTC-­‐negativen	   Patientinnen	   und	   vorhandener	  Progesteron	  Rezeptor-­‐Expression	  nachgewiesen	  werden.	  Zusammenfassend	  spielen	  IL-­‐1α	   und	   IL-­‐1β	   eine	   bedeutende	   Rolle	   bei	   der	   Freisetzung	   von	   CTCs	   in	   das	   periphere	  Blutsystem.	   In	  ähnlicher	  Weise	  zeigten	  TH2-­‐Zytokine	  signifikant	  veränderte	  Werte	  bei	  CTC-­‐negativen	  Patientinnen	  und	  der	  Progesteron	  Rezeptor-­‐Expression.	  Ein	  Anstieg	  von	  IL-­‐4	   scheint	   demzufolge	   auf	   den	   Hormonrezeptor-­‐Status	   angewiesen	   zu	   sein.	   IL-­‐4	  korreliert	  mit	  einer	  Apoptoseresistenz	  und	  kann	  demnach	  für	  das	  schlechte	  Ergebnis	  in	  diesen	   Fällen	   verantwortlich	   gemacht	   werden	   (51-­‐53,	   68).	   Erhöhte	   TH2-­‐Konzentrationen	  bei	  Brustkrebspatientinnen	  scheinen	  mit	  einer	  ungünstigen	  Prognose	  in	   Zusammenhang	   zu	   stehen.	   Die	   beschriebenen	   Zytokinprofile	   erlauben	   ein	  verbessertes	   Verständnis	   für	   Brustkrebs	   und	   verdeutlichen	   wie	   immunologisch	  relevante	   Gene	   die	   Karzinogenese	   beeinflussen.	   Die	   Messung	   und	   Interpretation	   von	  Zytokinprofilen	  könnte	  in	  der	  Zukunft	  von	  Nutzen	  sein,	  um	  das	  Risiko	  von	  Patientinnen	  zu	  dem	  Zeitpunkt	  der	  Erstdiagnose	  abzuschätzen	  und	  die	  Therapieoptionen	  anzupassen.	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Influence	  of	  circulating	  tumour	  cells	  on	  the	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  response	  of	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  habe.	  	  Ich	  erkläre	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CTC	   	   	   Circulating	  tumour	  cells	  
sFlt1	   	   	   Soluble	  fms-­‐like	  tyrosine	  kinase-­‐1	  
PIGF	   	   	   Phosphatidylinositol-­‐glycan	  biosynthesis	  class	  F	  protein	  
VEGF	   	   	   Vascular	  endothelial	  growth	  factor	  
ELISA	   	   	   Enzyme-­‐linked	  immunosorbent	  assay	  
TH1	  	   	   	   T	  helper	  1	  
TH2	   	   	   T	  helper	  2	  	  
TH17	   	   	   T	  helper	  17	  	  
Treg	   	   	   Regulatory	  T	  cells	  	  
TH9	   	   	   T	  helper	  9	  	  
IFN-­‐γ 	   	   	   Interferon	  gamma	  	  
TNF-­‐α	  	   	   Tumour	  necrosis	  factor	  alpha	  	  
IL-­‐12	   	   	   Interleukin	  12	  	  
IL-­‐1α	   	   	   Interleukin	  1	  alpha	  	  
IL-­‐1β	   	   	   Interleukin	  1	  beta	  	  
IL-­‐2	   	   	   Interleukin	  2	  	  
IL-­‐18	   	   	   Interleukin	  18	  	  
DFS	   	   	   Disease-­‐free	  survival	  	  
OS	   	   	   Overall	  survival	  	  
EpCAM	   	   Epithelial	  cell	  adhesion	  molecule	  	  
AUC	  	   	   	   Area	  under	  the	  curve	  	  
FEC	   	   	   Fluorouracil-­‐epirubicin-­‐cyclo-­‐phosphamide	  	  
CRP	   	   	   C-­‐reactive	  protein	  
NK	   	   	   Natural	  killer	  	  
HER2	   	   	   Human	  epidermal	  growth	  factor	  receptor	  2
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